2025 Program

At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.

The 2026 Program will be announced in mid-March. Explore our sessions and speakers from 2025 in the agenda below to see the caliber of programming you can expect at BIO 2026.

Loading
Search Filters
  • Date
  • Focus Area
  • Session Type
  • Location
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
4:15 PM (ET)
  1. AI Summit: What is Working? What is Next?
    After many years of research, AI-supported molecules have started entering clinical trials and the 2024 Nobel Prize in Chemistry recognized the impact of computational biology on reenvisioning the dru ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Speakers
    Luba Greenwood
    Luba Greenwood, Executive in Residence, PureTech Health ; Chief Executive Officer - Gallop Oncology
  2. Investors’ Perspectives – AI and Digital Health Investment Trends in 2025
    This panel of iconic healthcare and life sciences investors will share their perspectives on top areas for AI and digital health investment. Recent reports show that the number of AI deals in healthca ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Moderator
    Josh Seidenfeld
    Josh Seidenfeld, Partner - Cooley LLP
    Speakers
    Laura Veroneau
    Laura Veroneau, Managing Director - Optum Ventures
    Mike O'Brien
    Mike O'Brien, Partner - Valspring Capital
    Dan Gebremedhin
    Dan Gebremedhin, Partner - Flare Capital Partners
  3. AI in Biologics Drug Discovery: Analyzing the Competitive Landscape, Technical Approaches, and the Industry's Role
    This session aims to illuminate the cutting-edge technical approaches of AI-driven biologics drug discovery companies. Speakers will explore the ongoing R&D efforts in developing platforms and pipelin ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Moderator
    Darren Platt
    Darren Platt, Chief Data Officer - Montage Bio
    Speakers
    Georgia Lu
    Georgia Lu, Managing Partner - Magnet Ventures
    Alex Lugovskoy
    Alex Lugovskoy, CEO and Co-founder - Diagonal Therapeutics Inc
    Yue Webster
    Yue Webster, VP of Model Driven Drug Discovery - Eli Lilly and Company
    Vega Shah
    Vega Shah, PMM Lead, Healthcare & Life Sciences - NVIDIA
    Ashoka Madduri
    Ashoka Madduri, Head of Scientific Strategy and CI - mRNA CoE, Sanofi
  4. Company Presentations
    Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  5. Return on Innovation – Redefining ROI to Bridge Manufacturing and Investment
    Biomanufacturing innovations have the potential for high impact, delivering benefits that span financial gains and societal advancements. These breakthroughs can drive increased efficiencies, reduce c ...
    Breakout Session
    • Business Development and Investment
    205ABC
    Moderator
    John Schiel
    John Schiel, Program Manager, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)
    Speakers
    Alex Morgan
    Alex Morgan, Partner - Khosla Ventures
    Nabiha Saklayen
    Nabiha Saklayen, Co-Founder & CEO - Cellino
    Daria Fedyukina
    Daria Fedyukina, Program Manager, Health Science Futures - Advanced Research Projects Agency for Health (ARPA-H)
    Daniel Gibbs
    Daniel Gibbs, Co-Founder & CEO - Cirsium Biosciences
    Jonathan Hostens
    Jonathan Hostens, Vice President - Insight Partners
  6. BBC StoryWorks: “The Next Frontier” Films
    The most powerful health stories don’t just inform—they connect, inspire, and move audiences. By centering the real-life journeys of patients and practitioners, we create narratives that spark emotion ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Pam Mangat
    Pam Mangat, Head of Creative - BBC StoryWorks Commercial Productions
  7. Storytelling Stage
    The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #349)
  8. Oncology Investment Themes: Where is the Market Putting its Money?
    Across therapeutic areas, oncology is richest in depth of pipeline and variety of potential modalities/mechanisms of action. Of nearly 200 different products in Phase 3 alone, small molecules are now ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Ashwin Singhania
    Ashwin Singhania, Partner - Ernst & Young
    Speakers
    Liz Barrett
    Liz Barrett, CEO - Urogen
    Christopher Mortko
    Christopher Mortko, Vice President, Business Development & Licensing - Merck
    Jack Wu
    Jack Wu, Senior Director, Search & Evaluation, Global Oncology - Takeda
    Mark Chraplyvy
    Mark Chraplyvy, Vice President, US Business Operations - Daiichi Sankyo
  9. Leveraging the Accelerated Approval Pathway for Rare Diseases
    Since its inception in 1992, the FDA has greenlit nearly 300 new drugs under its accelerated approval pathway, with notable nods in oncology, Alzheimer’s disease, and amyotrophic lateral sclerosis. It ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    206AB
    Moderator
    Heather McKenzie
    Heather McKenzie, Senior Editor - BioSpace
    Speakers
    Camille Bedrosian
    Camille Bedrosian, Chief Medical Officer - Amylyx Pharmaceuticals, Inc.
    Emil Kakkis
    Emil Kakkis, President and CEO - Ultragenyx
    Joseph Ross
    Joseph Ross, Professor of Medicine and Public Health - Yale School of Medicine
  10. AI in Biopharma: What’s Working and What’s Left to Prove
    Artificial intelligence (AI) is already revolutionizing drug discovery and development by accelerating the identification of novel targets, optimizing molecules, and improving the efficiency of clinic ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Moderator
    Megan Nacar
    Megan Nacar, VP, Commercial - DeciBio
    Speakers
    Attila Csikasz-Nagy
    Attila Csikasz-Nagy, Co-founder & CEO - Cytocast
    Maria Luisa Pineda
    Maria Luisa Pineda, Co-founder & CEO - Envisagenics
    Jason Raeburn
    Jason Raeburn, Partner, Judge, Deputy Master of the High Court - Paul Hastings
    Rafael Rosengarten
    Rafael Rosengarten, Chief Executive Officer and Co-founder - Genialis
    Alex Zhavoronkov
    Alex Zhavoronkov, CEO & Founder - Insilico Medicine
  11. Preparing for the Next Generation in Antimicrobial Resistance: Combining Traditional with Non-Traditional Therapeutic Approaches to Tackle an Ongoing Pandemic
    The threat of antimicrobial resistance is growing globally as the use of higher doses and repeated courses of antibiotics drives more resistant bacteria. Yet innovation in infectious disease has been ...
    Breakout Session
    • Infectious Disease and Vaccines
    254A
    Moderator
    Steve St Onge
    Steve St Onge, Senior Vice President of Corporate Development - Clarametyx Biosciences
    Speakers
    Ella Balasa
    Ella Balasa, Patient Advocate and Advisor - Balasa Consulting
    Erin Duffy
    Erin Duffy, Chief of Research and Development - CARB-X
    Maud Eijkenboom
    Maud Eijkenboom, Managing Director - Lixa Pty Ltd
    Steve Sandor
    Steve Sandor, VP, Market Access, Trade and Government Affairs - Paratek Pharmaceuticals
    Judith Steenbergen
    Judith Steenbergen, Chief Executive Officer - Scientific and Medical Affairs Consulting
  12. Beyond Innovation: Supercharging America's Biomanufacturing Infrastructure
    The bioeconomy—encompassing industries that leverage biological resources, processes, and principles—spans sectors such as biotechnology, agriculture, pharmaceuticals, bioenergy, and synthetic biology ...
    Breakout Session
    • Biomanufacturing
    254B
    Moderator
    Vic Suarez
    Vic Suarez, Founder & Principal Growth Partner - Blu Zone Bioscience & Supply Chain Solutions
    Speakers
    Tim Belski
    Tim Belski, Program Director - Biopharmaceutical Manufacturing Preparedness (BioMaP) DHHS/ASPR/BARDA
    Paul Hill
    Paul Hill, SVP, Process Development & Engineering - Amyris
    Aji Parayil
    Aji Parayil, Founder & CEO - Manus
    Katherine Sixt
    Katherine Sixt, Principal Director for Biotechnology in the Office of the Under Secretary of Defense for Research and Engineering - US Department of Defense
    Phil Van Trump
    Phil Van Trump, Chief Science and Technology Officer - Danimer Scientific
  13. Effective Use of the New European Patent System as Part of Your Global Patent Strategy
    The new Unified Patent Court (UPC) system in Europe has been described as a game-changer with respect to patent litigation, particularly when there are infringing activities in both Europe and the Uni ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    209
    Moderator
    Alfonso Chan
    Alfonso Chan, Partner - Cahill Gordon & Reindel
    Speakers
    Robert Alderson
    Robert Alderson, Partner - United States and European Patent Attorney - Berggren Oy
    Jennifer Burdman
    Jennifer Burdman, Intellectual Property Strategist and Advisor - Sauvegarder Investment Management
    Arno Risse
    Arno Risse, Partner at ARNOLD RUESS - ARNOLD RUESS
  14. Shaping Strategies for Impact, Resilience and Lasting Value
    In a complex and ever-evolving landscape—with shifting regulatory pressures and stakeholder expectations—biotech and pharma companies must continue prioritizing transparency to build trust, maintain a ...
    Breakout Session
    • Environmental Sustainability
    208
    Moderator
    Sharon Gordon
    Sharon Gordon, Senior Vice President, Social Impact and Sustainability Lead - Syneos Health Communications
    Speakers
    Andrew Kaplan
    Andrew Kaplan, Senior Vice President of U.S. Public Affairs - Takeda Pharmaceuticals
    Carol Richardson
    Carol Richardson, Senior Director, Sustainability and Health Equity Lead, US - Teva Pharmaceuticals
    Michael Cohen
    Michael Cohen, Senior Director, Lead, Environmental Sustainability, PPDTM - Thermo Fisher Scientific
    Marc Siegel
    Marc Siegel, Co-Founder - Metrix Advisory
  15. Psychedelics Are Going Mainstream. Are You Ready For It?
    The therapeutic use of psychedelics is no longer a pipe dream – they are on the verge of potentially transforming the way we treat brain health disorders. As companies progress psychedelic therapies i ...
    Breakout Session
    • Brain Health
    251
    Moderator
    Moira Gunn
    Moira Gunn, Host of NPR's 'Tech Nation'; Director of the Bio-Entrepreneurship Program at the University of San Francisco - NPR 'Tech Nation'
    Speakers
    Sharmin Ghaznavi, MD, PhD
    Sharmin Ghaznavi, MD, PhD, Associate Director, Center for the Neuroscience of Psychedelics - Massachusetts General Hospital; Harvard Medical School
    Daniel Karlin
    Daniel Karlin, Chief Medical Officer - MindMed
    Michael Kobernick, MD
    Michael Kobernick, MD, Senior Medical Director - Blue Cross Blue Sheild of Michigan
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Katie Walker
    Katie Walker, Patient Advocate; Licensed Certified Social Worker, Registered Play Therapist - Patient; Indigo Counseling
  16. From Skepticism to Opportunity: Building Investor Confidence in First-in-Class and First-in-Disease Drug Innovation
    In recent years, investors have leaned toward being “risk off” for truly innovative therapies, such as first-in-class or first-in-disease drugs, with a preference for lower-risk drug discovery opportu ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Alan Crane
    Alan Crane, Entrepreneur Partner - Polaris Partners
    Speakers
    Kathy Dong
    Kathy Dong, President and Chief Executive Officer - Electra Therapeutics
    Rajiv Patni
    Rajiv Patni, CEO - Judo Bio
    Marc Schwabish
    Marc Schwabish, Chief Business Officer - Tectonic Therapeutic
    John Sundy
    John Sundy, Chief Medical Officer - Seismic Therapeutic
  17. Who Are Today’s Biotech Underdogs and What Will It Take for Them to Succeed?
    Today's undervalued category is tomorrow's over-crowded sector, yet newcomers are emerging. This panel will examine issues, opportunities, and approaches to dealmaking among an emerging generation of ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Max Bayer
    Max Bayer, Pharma Reporter - Endpoints News
    Speakers
    Deborah Baron
    Deborah Baron, Senior Vice President, Worldwide Business Development - Pfizer
    Steven Damon
    Steven Damon, CEO - Micron Biomedical, Inc.
    Jeffrey Meckler
    Jeffrey Meckler, CEO - Indaptus Therapeutics
    Tim Opler
    Tim Opler, Managing Director - Stifel
    Hanadie Yousef
    Hanadie Yousef, CEO and Co-Founder - Juvena Therapeutics
  18. Augmented Medicines: Use XR Headsets to See What Patients See (Try-It-Yourself Demos)
    Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
    257AB
    Speakers
    Gail Gannon
    Gail Gannon, CEO - Ensanté; Director, Neurotech Collider Lab, and Faculty, College of Engineering, University of California, Berkeley
    Mark Edwards
    Mark Edwards, CEO and Founder - ViewMind
    Ryan Glatt
    Ryan Glatt, Senior Brain Health Coach - Pacific Neurosciences Institute
    Todd Maddox
    Todd Maddox, Chief Science Officer - AppliedVR
    Julia Scott
    Julia Scott, CEO Gambit Labs & Director of Brain and Memory Care Lab - Santa Clara University
  19. Breaking Through: Overcoming Early Development Challenges
    Early drug development presents unique challenges for companies navigating the complexities of clinical programs, regulatory landscapes, and market access. This session will explore key trends impacti ...
    Breakout Session
    • Business Development and Investment
    258A

    Sponsored by:

    cencora

    Moderator
    Mike Day
    Mike Day, Senior Director, Regulatory Affairs US - Cencora
    Speakers
    Glenn Pauly
    Glenn Pauly, Former Chief Commercial Officer - Former Alzheon
    Alexandra Beumer Sassi
    Alexandra Beumer Sassi, Executive Director CMC Regulatory Biologics, Oncology - AstraZeneca
    Nina Hunter
    Nina Hunter, VP of Regulatory and Corporate Strategy - REGENXBIO
    Patroski Lawson
    Patroski Lawson, CEO - The KPM Group
    Matias Olsen
    Matias Olsen, Sr. Manager Public Affairs & Policy - EUCOPE
  20. Coming to America: The Role of State Governments in Supporting Life Sciences Companies for US Market Entry and Expansion
    This panel will focus on the role of state governments in supporting life sciences innovation in the United States, including programs that are offered at the state level to support international comp ...
    Breakout Session
    • Business Development and Investment
    205ABC
    Moderator
    Angus McQuilken
    Angus McQuilken, Business Development Associate Director – Life Sciences - Orrick
    Speakers
    Jonathan Thomas
    Jonathan Thomas, President and CEO - California Institute for Regenerative Medicine (CIRM)
    Katy Parker
    Katy Parker, Director of Project Management - Economic Development Partnership of North Carolina (EDPNC)
    Carla Reimold
    Carla Reimold, Executive Vice President of Scientific Innovation and Strategic Investments - Massachusetts Life Sciences Center
    Ken Smith
    Ken Smith, Chief Product Development Officer - Cancer Prevention and Research Institute of Texas (CPRIT)
  21. Expanding Access at the Speed of Innovation
    Innovative approaches to medicine require us to reimagine how we bring medicines to patients. This panel will explore the intersection of industry, policy, and the patient community and how collaborat ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    210B

    alnylam

     

    Moderator
    Tolga Tanguler
    Tolga Tanguler, Chief Commercial Officer - Alnylam Pharmaceuticals
    Speakers
    Christina Hartman
    Christina Hartman, Senior Director, Government Affairs - Orchard Therapeutics
    Shannon Deere
    Shannon Deere, Director - Leavitt Partners
    John Feore
    John Feore, Senior Director of Health & Reimbursement Policy - Kimbell Associates
  22. The Disorder Channel Films
    Unconditional: Raising a Glass Child with a PACS1 Sibling - This film introduces the Poague Zellinger family who are facing PACS1 syndrome which affects their five year old son Finn. The phrase glass ...
    Storytelling Stage Storytelling Stage (Booth #349)
  23. Start-Up Stadium Monday
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  24. We’ve Entered a New Era of Neuropsychiatry: Precision in Practice
    For too long, psychiatry has relied solely on clinical observation to prescribe treatments, overlooking the biological differences that impact how patients respond to medication. This trial-and-error ...
    Breakout Session
    • Brain Health
    251
    Moderator
    Rowan Walrath
    Rowan Walrath, Associate Editor - Chemical & Engineering News
    Speakers
    Katherine Burdick
    Katherine Burdick, Professor of Psychology, Department of Psychiatry, Brigham and Women's Hospital - Harvard Medical School
    Jacob Donoghue
    Jacob Donoghue, CEO & Co-Founder - Beacon Biosignals
    Patricio O’Donnell
    Patricio O’Donnell, VP, Translational Medicine - Alto Neuroscience
  25. Journey Into the [Un]validated – A Practical Guide to Partnering Early with Pharma on Novel Drug Modalities
    siRNA, mRNA, pick-your-favorite-RNA, CRISPR, ADCs, PROTACs, molecular glues, precision-meds, CAR-T, epigenetic and allosteric modulators, AI/ML-everything, tissue-selective nanoparticles, AAV delivery ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Amanda Kay
    Amanda Kay, Senior Partner, Chief Business Development Officer - Flagship Pioneering
    Speakers
    Barbara Lueckel
    Barbara Lueckel, Global Head of Research Technologies - Roche
    Svetlana Lucas
    Svetlana Lucas, Chief Business Officer - Scribe Therapeutics
    Michael Palladinetti
    Michael Palladinetti, Global Head of Immunology & Inflammation Business Development - Sanofi
    Caroline Stark Beer
    Caroline Stark Beer, Chief Business Officer - Jnana Therapeutics
  26. How to Best Scale CGT Manufacturing: Bringing Together Disparate Approaches
    Cell and gene therapies (CGT) are proving their worth as life-saving treatments, from cancers to rare diseases, but bringing these innovations to the masses will require substantial advances in manufa ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    206AB
    Moderator
    Jef Akst
    Jef Akst, Managing Editor - BioSpace
    Speakers
    Jason Foster
    Jason Foster, Chief Executive Officer - Ori Biotech
    Josh Ludwig
    Josh Ludwig, Global Director Commercial Operations - Wilson Wolf
    Michael Paglia
    Michael Paglia, Chief Technology Officer - ElevateBio
    Courtney Rice
    Courtney Rice, Principal - Acadia Strategy Partners
    Audrey Greenberg
    Audrey Greenberg, Mayo Venture Partner & Chair, Department of Business Development - Mayo Clinic
  27. Rapid Response Capabilities of Global Health and Biosecurity Countermeasures During Outbreaks - Leveraging Public Private Partnerships
    This session will explore how CEPI (Coalition for Epidemic Preparedness Innovations) and its global partners mobilize during an outbreak, highlighting how strategic partnerships and rapid vaccine deve ...
    Breakout Session
    • Infectious Disease and Vaccines
    254A
    Moderator
    Emma Wheatley
    Emma Wheatley, Executive Director Access and Business Development - CEPI
    Speakers
    Amy Finan
    Amy Finan, CEO - Sabin Vaccine Institute
    Holger Kissel
    Holger Kissel, SVP, Scientific Relations & Liaison - BioNTech
    Vicky Leamy
    Vicky Leamy, Vice President, Therapeutic Science and Strategy - IQVIA
  28. European Biotech: Unlocking Investment Opportunities
    Over the past decade, European biotech has seen remarkable growth, driven by increasing early-stage investments and the creation of promising start-ups. VIB, a leading life sciences research institute ...
    Breakout Session
    • Business Development and Investment
    204AB
    Moderator
    Selina Koch
    Selina Koch, Executive Editor, Head of Intelligence & Research - BioCentury Inc.
    Speakers
    Matthew Foy
    Matthew Foy, CEO - Avante Biocapital
    Renée Lucander
    Renée Lucander, CEO - Hansa Biopharma
    Christina Takke
    Christina Takke, Managing Partner - V-Bio Ventures
    Jérôme Van Biervliet
    Jérôme Van Biervliet, Managing Director - VIB
  29. Understanding and Mitigating the Consequences of Loper Bright, Corner Post & Judicial Activities on Drug Development, Commercialization, and Investment
    While the industry is moving forward with the blending of technology and science, the legal landscape is quite different in one of the largest markets: the United States. The Loper Bright ruling this ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    209
    Moderator
    Lori Ellis
    Lori Ellis, Head of Insights - BioSpace
    Speakers
    Chris Hart
    Chris Hart, Partner - Foley Hoag
    Konstantina Katcheves
    Konstantina Katcheves, Senior Vice President, Innovative Medicines Business Development - Teva Pharmaceuticals
    Michelle Longmire
    Michelle Longmire, CEO & Co-founder - Medable
    Edie Stringfellow
    Edie Stringfellow, SVP, Global Health Strategy and Biomedical Commercialization - Precia Group
  30. Integrating AI-Driven Drug Discovery to Improve R&D Supply Chain Efficiency
    Artificial intelligence (AI) and related technologies offer new avenues of drug discovery productivity never before possible. These innovative methods not only provide significant value to the biophar ...
    Breakout Session
    • Biomanufacturing
    254B
    Moderator
    Uduak Thomas
    Uduak Thomas, Senior Editor - Genetic Engineering & Biotechnology News
    Speakers
    Lee Cronin
    Lee Cronin, Chief Executive Officer and Chief Scientific Officer - Chemify
    Raphael Townshend
    Raphael Townshend, Founder and Chief Executive Officer - Atomic AI
    Woody Sherman
    Woody Sherman, Founder and Chief Innovation Officer - Psivant Therapeutics
    Ruediger Weseloh
    Ruediger Weseloh, Executive Director of Business Development - EMD Serono
  31. Healthcare AI Opportunities and Headwinds at NIH and the Ecosystem at Large: Fulfilling the Promise or Machine Learning Impaired?
    Healthcare AI as we know it is evolving at a rapid pace, with major tech company initiatives, overheated equity investment and the next generation of innovation fanning the flames. How can NIH and maj ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Moderator
    Michael Salgaller
    Michael Salgaller, Supervisory Specialist, Technology Transfer Center - National Institutes of Health
    Speakers
    Caroline Chung
    Caroline Chung, Vice President, Chief Data & Analytics Officer - MD Anderson Cancer Center
    Bill Fitzgerald
    Bill Fitzgerald, Head of Biotechnology Markets Americas, Google Cloud - Google
    Martin Gershon
    Martin Gershon, Managing Partner & Chief Strategy Officer, Endeavor Venture Group - Senior Lead Mentor-in-Residence Techstars, Advisor White House CancerX Moonshot Accelerator
    Belinda Seto
    Belinda Seto, Deputy Director, Office of Data Science Strategy - National Institutes of Health
  32. Preparing for an IPO: Best Practices for Success
    For biotech companies planning an IPO, navigating market dynamics, investor expectations, and regulatory hurdles is critical to success. This session brings together industry leaders to share insights ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Kimberly Ha
    Kimberly Ha, CEO - KKH Advisors
    Speakers
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Jennifer Fang
    Jennifer Fang, Partner - Wilson Sonsini
    Andrew Lam
    Andrew Lam, Managing Director, Head of Biotech Private Equity - Ally Bridge Group
    Jordan Saxe
    Jordan Saxe, Head of Healthcare Listings - NASDAQ
    Chirag Surti
    Chirag Surti, Executive Director, Global Capital Markets - Morgan Stanley
  33. Fireside Chat
    Fireside Chat with Dava Sobel, author of "The Elements of Marie Curie: How the Glow of Radium Lit a Path for Women in Science"
    Even now, nearly a century after her death, Marie Curie remains the only female scientist most people can name. She gained world renown at age thirty-six, when she received the first of her two Nobel ...
    Fireside Chat
    • Oncology
    210B
    Moderator
    Shiva Malek
    Shiva Malek, Global Head of Oncology Disease Area - Novartis Institute for BioMedical Research, Inc.
    Speakers
    Dava Sobel
    Dava Sobel - Author, "The Elements of Marie Curie: How the Glow of Radium Lit a Path for Women in Science"
  34. Voices from Biotech
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Susan Roberts
    Susan Roberts, Founder - Roberts Communications
    Speakers
    Lori Lindburg
    Lori Lindburg, Co-Founder / Sr. Advisor - Life Sciences Workforce Collaborative (LSWC)
    Roger Royse
    Roger Royse, Partner - Haynes Boone
    Kelvyn Cullimore
    Kelvyn Cullimore, CEO - Bio Utah
    Luke Timmerman
    Luke Timmerman, founder and editor - Timmerman Report
    Susan Pandya
    Susan Pandya, Global Head of Oncology Clinical Development Late Stage and LCM - Servier Pharmaceuticals
    Liisa Bozinovic
    Liisa Bozinovic, Chair - Life Sciences Workforce Collaborative (LSWC)
  35. Unlocking the Power of Global Trade: Did You Know 95% of the World’s Buying Power is Outside of the United States?
    In today’s global economy it is imperative U.S. companies maintain a competitive advantage by understanding industry developments across global markets. The most successful companies embrace internati ...
    Breakout Session
    • Business Development and Investment
    205ABC
  36. Augmented Medicines: Use XR Headsets to See What Patients See (Try-It-Yourself Demos)
    Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
    257AB
    Speakers
    Gail Gannon
    Gail Gannon, CEO - Ensanté; Director, Neurotech Collider Lab, and Faculty, College of Engineering, University of California, Berkeley
    Julia Scott
    Julia Scott, CEO Gambit Labs & Director of Brain and Memory Care Lab - Santa Clara University
  37. Regulatory Acceleration & Innovation: Leveraging New Policies for a Smarter Biopharma Go-to-Market Strategy
    The evolving regulatory landscape is opening new doors for biopharma companies to bring therapies to market faster and more efficiently. Programs like the FDA’s Advanced Manufacturing Platform (AMT), ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    208

    Sponsored by:

    cytiva

    Moderator
    Michael Ryskin
    Michael Ryskin, Managing Director, Life Science Tools & Diagnostics, Animal Health - BofA Securities, Inc.
    Speakers
    Angela Johnson
    Angela Johnson, Head of Global Regulatory and Compliance - Cytiva
    Bassem Gayed
    Bassem Gayed, Senior Director, Cell Therapy Technical Operation - Bristol Myers Squibb
    Danielle Corwin
    Danielle Corwin, Chief of Staff, Regulatory Strategy and Business Excellence - Global Regulatory Affairs, Specialty Care, Sanofi
    Pamela Stetkiewicz
    Pamela Stetkiewicz, Chief Operating Officer - Arbor Biotechnologies
  38. The Future of Cancer Care: The Pursuit of Progress Towards Cures
    Cancer care is at a pivotal moment. Breakthroughs in precision medicine, immunotherapy, artificial intelligence and data-driven diagnostics are transforming how we detect, treat and manage cancer. Yet ...
    Breakout Session
    • Oncology
    258A

    Sponsored by:

    merck

    Moderator
    Ben Comer
    Ben Comer, Chief Editor - Life Science Leader magazine
    Speakers
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Pam Traxel
    Pam Traxel, Senior Vice President - American Cancer Society Cancer Action Network, Inc.
    Christiana Iyasere
    Christiana Iyasere
    Elsa Beyer Krall
    Elsa Beyer Krall, Director, Discovery Oncology - Merck
  39. Translating Nobel Prize Science into the Clinic
    In 1901, the first Nobel Prize was awarded to recognize those who “have conferred the greatest benefit to humankind.” Often the work that goes into winning this prestigious award occurs over decades a ...
    Breakout Session
    • Translational Research
    258A
    Moderator
    Barbara Cheifet
    Barbara Cheifet, Chief Editor - Nature Biotechnology
    Speakers
    Eamonn Hobbs
    Eamonn Hobbs, President and Chief Executive Officer - Syncromune
    Sharon Rosenzweig-Lipson
    Sharon Rosenzweig-Lipson, Chief Scientific Officer - Life Biosciences
    Michael Severino
    Michael Severino, Chief Executive Officer - Tessera Therapeutics
    John Lepore
    John Lepore, Chief Executive Officer - ProFound Therapeutics
  40. Foundation Models for Genomics: Current Advances and Future Directions
    The rapid advancement of DNA foundation models is transforming our ability to decode complex genomic patterns and regulatory mechanisms. This session will explore the current state of these models, th ...
    Breakout Session
    • AI and Digital Health
    253ABC
    Moderator
    Martin Gershon
    Martin Gershon, Managing Partner & Chief Strategy Officer, Endeavor Venture Group - Senior Lead Mentor-in-Residence Techstars, Advisor White House CancerX Moonshot Accelerator
    Speakers
    Vikram Agarwal
    Vikram Agarwal, Head of mRNA Platform Design Data Science, mRNA Center of Excellence - Sanofi
    Tommaso Biancalani
    Tommaso Biancalani, Senior Director and Head of AI for Research Biology - Genentech, a member of the Roche Group
    Peter Koo
    Peter Koo, Associate Professor - Cold Spring Harbor Laboratory
    Amber Tang
    Amber Tang, Research Scientist - InstaDeep
  41. The Priority Review Voucher Program: Incentivizing Neglected Disease Research and Promoting Biotech Investment and Development for More than a Decade
    This session will explore the priority review voucher (PRV) program as proposed in a 2006 paper by Ridley, Grabowski, and Moe and became law in 2007. The PRV allowed the FDA to encourage R&D in neglec ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Edward Diehl
    Edward Diehl, Commercialization Officer - Defense Health Agency
    Speakers
    Barry Datlof
    Barry Datlof, Chief, Business Development and Commercialization, Office of Medical Technology Transfer - U.S. Army Medical Research and Material Command
    Steven Ferguson
    Steven Ferguson, Special Advisor, NIH Office of Technology Transfer - National Institutes of Health
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Patient Advocacy - Biotechnology Innovation Organization (BIO)
    David Ridley
    David Ridley, Faculty Director for the Center for Health Sector Management - Duke University
    Chris Porter
    Chris Porter, Vice President - Travere Therapeutics
  42. Platform Licensing: Biotech and Pharma Perspectives
    This past year has seen many early-stage deals involving platform technologies ranging from AI drug discovery to building blocks for gene therapy products. In this panel, speakers will explore platfor ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Oren Livne
    Oren Livne, Partner - Baker McKenzie
    Speakers
    Casarine Chong
    Casarine Chong, Senior Vice President, Deputy General Counsel, Transactions - Bristol Myers Squibb
    L. Gavin Liu
    L. Gavin Liu, Managing Partner - Liu Legal Consulting
    Ellen Lubman
    Ellen Lubman, Advisor - Werewolf Therapeutics, Aronora, Two Bear Capital
    Maria Nichol
    Maria Nichol, Chief Business Officer - Artax Biopharma
    Deepa Talpade
    Deepa Talpade, Vice President, Head BD&L and Alliance Mgmt., Oncology - Bayer
  43. Profit and Access: Groundbreaking Strategies to Make Medicines Available in Resource-Challenged Markets
    There is much to be said for the humanitarian impulse to expand access to life-saving medicines in resource challenged geographies, but the realities on the ground tell us that the humanitarian impuls ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    208
    Moderator
    Jeffrey Sturchio
    Jeffrey Sturchio, Chair - Friends of the Global Fight Against AIDS, Tuberculosis and Malaria
    Speakers
    Aparna Parikh
    Aparna Parikh, Associate Professor of Medicine and Director MGH Cancer Center Global Cancer Care Program - Harvard Medical School and Massachusetts General Hospital
    Clifford Samuel
    Clifford Samuel, Former SVP, Global Patient Solutions - Gilead Sciences, Inc.
    Keith Flaherty
    Keith Flaherty, Director of Clinical Research - Massachusetts General Hospital Cancer Center
    Anand Reddi
    Anand Reddi, Corporate Vice President, Global Strategic Initiatives and Corporate Operations - BeOne Medicines
    Amy Israel
    Amy Israel, Senior Advisor, Access to Medicines - Union for International Cancer Control
  44. It’s Not “Just the Flu”: Harnessing Innovation to Save Lives
    The session explores novel technologies and public-private partnerships that can end deaths from influenza in our lifetime. Last flu season saw illnesses, medical visits, hospitalizations, and deaths ...
    Breakout Session
    • Infectious Disease and Vaccines
    254A
    Moderator
    Niki Carelli
    Niki Carelli, Senior Vice President, The Daschle Group - Executive Director, Coalition To Stop Flu
    Speakers
    Jacob Glanville
    Jacob Glanville, CEO - Centivax
    Ken Kelley
    Ken Kelley, CEO - IDBiologics, Inc.
    Marcus Lacey
    Marcus Lacey, Executive Director - Global Pandemic Head - CSL Seqirus
    Michele Slafkosky
    Michele Slafkosky, Executive Director - Families Fighting Flu
    Steven Cagas
    Steven Cagas, Senior Medical Science Director-Xofluza and Xolair - Genentech
  45. Examining Innovative Business Models for Creating Sustainable Network and Capabilities for Public Health and Biosecurity Countermeasures
    As biological threats evolve, traditional stockpiling strategies need to adapt to ensure both readiness and flexibility. This session will delve into dual-use models that serve commercial and public h ...
    Breakout Session
    • Business Development and Investment
    206AB
    Moderator
    Emma Wheatley
    Emma Wheatley, Executive Director Access and Business Development - CEPI
    Speakers
    Derrick Sim
    Derrick Sim, Managing Director of Vaccine Markets, Health Security & COVAX - GAVI The Vaccine Alliance
    Rajinder Kumar Suri
    Rajinder Kumar Suri, CEO - Developing Countries Vaccine Manufacturers Network (DCVMN) International
    Lynda Stuart
    Lynda Stuart, President and Chief Executive Officer - Fund for Science and Technology Washington
    Glenn Rockman
    Glenn Rockman, Founder and Managing Partner - Adjuvant Global Health Technology Fund
  46. Fuel Your Innovative Cancer Breakthrough: From Unlocking Dilutive and Non-Dilutive Funding to Fostering Fruitful Partnerships
    Getting a foothold in the biotech industry isn’t easy. If you have a game-changing biotech idea that will make a difference for cancer patients, you’ll need funding and entrepreneurship expertise to t ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Farnaz Bakhshi
    Farnaz Bakhshi, Director, Innovation - American Cancer Society BrightEdge
    Speakers
    Brittany Connors
    Brittany Connors, Director of Investor Relations - NCI SBIR
    Dione Kobayashi
    Dione Kobayashi, Head of Therapeutics and Partner - Amplify
    Douglas Hurst
    Douglas Hurst, Scientific Director - American Cancer Society
    Kristin Sherman
    Kristin Sherman, CEO - Kovina Therapeutics
    Javeed Froozan
    Javeed Froozan, VP, Business Development & Strategic Alliances - The Leukemia & Lymphoma Society
  47. Intellectual Property Considerations for Inventions Made By, Or Involving, Artificial Intelligence
    As it has touched so many different areas of human activity, so has artificial intelligence (AI) touched biotechnology and, by extension, biotechnology intellectual property. Panelists will discuss th ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    209
    Moderator
    John Storella
    John Storella, Partner - Storella & Witt
    Speakers
    Ali Alemozafar
    Ali Alemozafar, Partner - Wilson Sonsini Goodrich & Rosati
    Amy Feng
    Amy Feng, Partner and Co-founder - Wu, Feng & Zhang
    Madhuri Roy
    Madhuri Roy, Partner - Cooley, LLP
    Marc Wilkinson
    Marc Wilkinson, Partner - J A Kemp LLP
    Zhen Zhang
    Zhen Zhang, Associate Director, Center for Biomarker Discovery and Translation - Johns Hopkins University
  48. Beyond the Contract: Building Successful Biotech Partnerships
    In a recent survey, overall partner ratings by large pharma customers were much higher in comparison to ratings given by smaller biotechs, displaying a potential disparity in how partner organizations ...
    Breakout Session
    • Biomanufacturing
    254B
    Moderator
    Tyler Menichiello
    Tyler Menichiello, Chief Editor - Bioprocess Online
    Speakers
    Jim Beach
    Jim Beach, CEO - Bexion Pharmaceuticals
    Jessica Blomberg
    Jessica Blomberg, Founder & CEO - Quality CMC Consulting
    Eric Cunningham
    Eric Cunningham, VP, CMC & Process Development - Sequoia Vaccines
    Rose Rhomberg
    Rose Rhomberg, Senior Director, Sales and Business Development - Cytovance Biologics
    Robert Tragas
    Robert Tragas, Executive Director of Laboratory Operations - Alcami
  49. Next-Generation Alzheimer's Disease Therapies
    As the search for effective treatments for Alzheimer’s disease intensifies, join us for a compelling panel discussion on the next-generation therapies reshaping the landscape of this devastating condi ...
    Breakout Session
    • Brain Health
    251
    Moderator
    Phyllis Ferrell
    Phyllis Ferrell, Chief Impact Officer - Alzheimer’s Moonshot - Startup Health
    Speakers
    Christian Howell
    Christian Howell, CEO - Cognito Therapeutics
    Beth Hoffman
    Beth Hoffman, Founder and CEO - Origami Therapeutics, Inc.
    Maha Radhakrishnan
    Maha Radhakrishnan, Executive Partner, Private Equity - Sofinnova Investments
    Mike Zuendel
    Mike Zuendel, Founder and Advocate-in-Chief - Initiative to Change the “D-Word”
  50. Book Signing with Dava Sobel author of "The Elements of Marie Curie: How the Glow of Radium Lit a Path for Women in Science" [Complimentary Book]
    Following her fireside chat, join Dava Sobel for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book signing ...
    Special Program
    • Special Program
    NW Lobby
  51. Augmented Medicines: Use XR Headsets to See What Patients See (Try-It-Yourself Demos)
    Extended reality (XR) sensory technologies enhance patient agency. This multi-purpose tool elevates patient education, provider communication, multi-dimensional therapy, and comprehensive assessments. ...
    Special Program
    • AI and Digital Health
    257AB
    Speakers
    Gail Gannon
    Gail Gannon, CEO - Ensanté; Director, Neurotech Collider Lab, and Faculty, College of Engineering, University of California, Berkeley
    Julia Scott
    Julia Scott, CEO Gambit Labs & Director of Brain and Memory Care Lab - Santa Clara University
  52. Let’s Talk About Sex (Differences)!
    For too long, women’s health has been overlooked, in research, in funding, and in the way we understand disease. But the science is clear: understanding sex differences doesn’t just improve health out ...
    Special Program
    • Special Program
    210B
    Moderator
    Michele Oshman
    Michele Oshman, Chief Patient Advocate and Head, Patient Advocacy Center of Excellence - Biotechnology Innovation Organization (BIO)
  53. ARPA-H's Flexible R&D Funding Model for Innovative Health Solutions
    Hear from Advanced Research Projects Agency for Health (ARPA-H) leadership and agency program and project performers as they discuss the agency’s efficient and unique model to fund health-related rese ...
    Breakout Session
    • Business Development and Investment
    205ABC
    Moderator
    Craig Gravitz
    Craig Gravitz, Mission Office Director, Project Accelerator Transition Innovation Office (PATIO) - Advanced Research Projects Agency for Health (ARPA-H)
    Speakers
    David Fajgenbaum
    David Fajgenbaum, Co-Founder & President - Every Cure
    Amy Jenkins
    Amy Jenkins, Acting Deputy Director - Advanced Research Projects Agency for Health (ARPA-H)
    Wade Shen
    Wade Shen, Mission Office Director, Proactive Health - Advanced Research Projects Agency for Health (ARPA-H)
    Pierre Dromel
    Pierre Dromel, CTO & Founder - InGel Therapeutics, Inc.
4:15 PM (ET)
  1. Tuesday Featured Program: An Exclusive Conversation with George W. Bush, 43rd President of the United States and Founder of the George W. Bush Presidential Center
    Please see the important note below about bags not being allowed in this session. We’re honored to host special guest George W. Bush, 43rd President of the United States and Founder of the George W. B ...
    Featured Program
    • Special Program
    Speakers
    George Bush
    George Bush - 43rd President of the United States and Founder of the George W. Bush Presidential Center
  2. Company Presentations
    Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  3. Global Supply Chain and CDMO Capacity
    BioProcess International Theater
    • Biomanufacturing
    Bioprocess Theater
  4. Global Innovation Hub Morning Presentations
    Global Innovation Hub Session 152
  5. Patient Diversity and Access to New Medicines – Can AI Improve Access in Disadvantaged Patient Populations and Optimize the Economics of Medical Innovation?
    The US life science industry and ecosystem have been an unparalleled engine for transformative medical innovation since the passage of the Bayh-Dole Act in 1980. Since then and through 2022, fueled by ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Drew Cutshaw
    Drew Cutshaw, Principal - Pappas Capital
    Speakers
    Murray Aitken
    Murray Aitken, Executive Director - IQVIA Institute for Human Data Science
    William Crown
    William Crown, Distinguished Research Scientist - Heller School for Social Policy and Management
    Marianne Hamilton Lopez
    Marianne Hamilton Lopez, Senior Research Director of Biomedical Innovation - Duke Margolis Institute for Health Policy
    Kimberly Borzillo
    Kimberly Borzillo, Director of Global Commercial Data Strategy and Innovation - Merck
    Taimur Khan
    Taimur Khan, Director - The Fenway Institute
  6. From Discovery to Deals: Bridging the Valley-of-Death with a Molecule-to-Medicine Expressway
    “Insanity is doing the same things over and over but expecting different results,” Rita Mae Brown. Most of us would agree. And yet, year after year, we invest over $90 billion in R&D, only to face a s ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Karim Budhwani
    Karim Budhwani, CEO-Scientist - CerFlux
    Speakers
    Kara Bortone
    Kara Bortone, Senior Director, J&J Innovative Medicine Business Development - Johnson & Johnson
    Sandeep Menon
    Sandeep Menon, Chief Development Officer, Head of Development and Safety - Alnylam
    Christopher Mortko
    Christopher Mortko, Vice President, Business Development & Licensing - Merck
    Maggie Scully
    Maggie Scully, Partnership Development Director - Frederick National Laboratory for Cancer Research
  7. Shifting Attitudes Toward Vaccines Among Lawmakers
    In recent years, public health advocacy has played an increasingly critical role in shaping legislation and policy decisions regarding vaccines. Shifting political landscapes, public opinion, and misi ...
    Breakout Session
    • Infectious Disease and Vaccines
    254A
    Moderator
    Phyllis Arthur
    Phyllis Arthur, Executive Vice President & Head of Healthcare Policy and Programs - Biotechnology Innovation Organization (BIO)
    Speakers
    Sherri Berger
    Sherri Berger, Founder and CEO - SB Strategies
    Luciana Borio
    Luciana Borio, Senior Fellow for Global Health - Council on Foreign Relations
    Larry Bucshon
    Larry Bucshon, Senior Policy Advisor and Former Member of Congress - Holland and Knight LLP
  8. Navigating Regulations to Bring Cell/Gene Therapies to Patients in Europe and Middle East
    From R&D, regulatory approval pathways to considerations for launching cell and gene therapies, this session is intended to shed a light on European and Middle Eastern (focus on Saudi Arabia and UAE) ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    206AB
    Moderator
    Els Janssens
    Els Janssens, Counsel - Baker McKenzie
    Speakers
    Georgia Gavriilidou
    Georgia Gavriilidou, Head of Legal Department - European Medicines Agency
    Laura Liebers
    Laura Liebers, Director, Head of Global Regulatory Intelligence - Vertex Pharmaceuticals
    Hashmi Shahrukh
    Hashmi Shahrukh, Director of Research, Professor of Medicine - Department of Health Abu Dhabi; Mayo Clinic, Rochester, Minnesota, United States
    Cristiane Ferreira
    Cristiane Ferreira, Executive Legal Director, Global Rare and Partner & Emerging Markets - Alnylam Pharmaceuticals
  9. Scalable Biomanufacturing for Living Medicines: Pioneering the Future Today
    As the demand for personalized therapies increases, the ability to efficiently produce living medicines at scale is more critical than ever. This session will explore cutting-edge advancements in biom ...
    Breakout Session
    • Biomanufacturing
    209
    Moderator
    Marinna Madrid
    Marinna Madrid, Co-Founder and Chief Product Officer - Cellino
    Speakers
    Bruna Paulsen
    Bruna Paulsen, VP, Manufacturing and Therapeutic Development - Gameto
    Alexis Rovner
    Alexis Rovner, CEO & Founder - 64x Bio
    Kate Rochlin
    Kate Rochlin, Chief Operating Officer - IN8bio
    Julie O’Shaughnessy
    Julie O’Shaughnessy, Chief Operating Officer - Vivodyne
  10. Advancing Innovative Risk-Stratification Tests that Impact Treatment Pathway Decisions: Challenges in Overcoming Barriers to Entry
    Developing innovative diagnostic tests that address unmet clinical needs and improve upon standards of care requires a significant investment of time and resources. Precision medicine companies willin ...
    Breakout Session
    • Diagnostics and Personalized Medicine
    251
    Moderator
    Michael Ryan
    Michael Ryan, Partner - McDermott Will & Emery
    Speakers
    Mara Aspinall
    Mara Aspinall, Partner - Illumina Ventures
    Gillian Hooker
    Gillian Hooker, Chief Scientific Officer - Concert
    Derek Maetzold
    Derek Maetzold, Founder, President and CEO - Castle Biosciences
  11. How VCs Evaluate Risk in Early Stage Startups
    How do venture capitalists evaluate early stage life science companies to decide where to place their bets? Learn how high-profile VCs evaluate startups, and what data sets are most important for earl ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Cristina Ghenoiu
    Cristina Ghenoiu, Partner - Mubadala Capital
    Jernej Godec
    Jernej Godec, Principal - Atlas Venture
    Kouki Harasaki
    Kouki Harasaki, Managing Director - Ikigai BioVentures
    Rebecca Silberman
    Rebecca Silberman, Investment Director - RA Capital Management
  12. Patient-Reported Outcomes are Front and Center for Drug Development AND with the FDA and the CDC
    Women on social media sites (TikTok) have been speaking out about IUD pain, with some describing the procedure as “the worst pain imaginable” or saying they “almost passed out.” Duke University resear ...
    Breakout Session
    • Regulatory Innovation
    254B
    Moderator
    Mary Beth Cicero
    Mary Beth Cicero, Founder & CEO - 3Daughters, Inc.
    Speakers
    Nancy Kivel
    Nancy Kivel, Senior Vice President, Global Health General Medicine, and Section Head Women's Health - Parexel International
    Aaron Lazorwitz
    Aaron Lazorwitz, Assistant Professor, Div. of Complex Family Planning & Reproductive Sciences - Yale University School of Medicine
    Kelsey Craig
    Kelsey Craig
    Christina Chang
    Christina Chang, Director, Division of Urology, Obstetrics and Gynecology (DUOG) - U.S. Food and Drug Administration
  13. Fireside Chat
    Fireside Chat with Dr. William Pao, author of "Breakthrough: The Quest for Life-Changing Medicines"
    What does it take to create a new medicine? The trajectory from laboratory to your neighborhood chemist rarely runs in a straight line. Eureka moments come few and far between. Drug discoveries demand ...
    Fireside Chat
    • Business Development and Investment
    205ABC
    Moderator
    Grace Colón
    Grace Colón, Chair, Bloom Science; - Board Member, BIO, Emm, MIT, Voyager Therapeutics
    Speakers
    William Pao
    William Pao - Author, "Breakthrough: The Quest for Life-Changing Medicines"
  14. Economic Development Policy and Partnerships in Biomanufacturing: State and Regional Perspectives
    Public-private partnerships and supportive state legislative measures aimed at growing biomanufacturing capacity in the United States are providing significant economic on-shoring value, and are essen ...
    Special Program
    • Biomanufacturing
    210B
    Moderator
    Pete Pellerito
    Pete Pellerito, Senior Policy Adviser Federal/State Economic Development & Technology Transfer Lead - BIO
    Speakers
    John Conrad
    John Conrad, Council of State Bioscience Associations, Chair; President & CEO - iBio
    Laura Rowley
    Laura Rowley, Vice President, Life Sciences Economic Development - North Carolina Biotechnology Center
    Matthew Szuhaj
    Matthew Szuhaj, Vice President - Strategic Development Group
    Ashley Stolba
    Ashley Stolba, Interim Secretary - Executive Office of Economic Development
    Joe Hamel
    Joe Hamel, Acting Enabling Innovations and Technologies Office Director and Senior Advisor, Center for Industrial Base Management and Supply Chain - Administration for Strategic Preparedness and Response (ASPR)
  15. Storytelling Stage
    The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #349)
  16. The Rare Disease Promise of Externally Led Scientific Focused Drug Development Meetings
    Since the passage of 21st Century Cures, FDA collaboration with the rare disease patient and scientific community has never been greater. The creation of a Rare Disease Innovation Hub also holds promi ...
    Breakout Session
    • Orphan and Rare Disease
    258A

    Sponsored by:

    travere

    Moderator
    Chris Porter
    Chris Porter, Vice President - Travere Therapeutics
  17. Voices from Biotech
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Michele Oshman
    Michele Oshman, Chief Patient Advocate and Head, Patient Advocacy Center of Excellence - Biotechnology Innovation Organization (BIO)
    Susan Roberts
    Susan Roberts, Founder - Roberts Communications
  18. Start-Up Stadium Tuesday morning
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  19. Optimizing Oncology Development: How to Thrive in Today’s Biotech Environment
    As the biotech industry faces growing complexity in regulatory expectations and clinical trial innovation, oncology developers must adopt smarter, more agile strategies to advance their pipelines. Pan ...
    Breakout Session
    • Oncology
    208

    Sponsored by:

    parexel biotech

    Moderator
    Charlotte Moser
    Charlotte Moser, Chief Medical Officer - Parexel
    Speakers
    Jakob Dupont
    Jakob Dupont, Executive Partner - Sofinnova Investments
    Paul Bridges
    Paul Bridges, President - Consulting - Parexel
    Samir Khleif
    Samir Khleif, CEO - Georgiamune
  20. Book Signing with Dr. William Pao, author of "Breakthrough: The Quest for Life-Changing Medicines" [Complimentary Book]
    Following his fireside chat, join Dr. William Pao for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book si ...
    Special Program
    • Business Development and Investment
    NW Lobby
  21. Super Session
    Navigating Barriers on the Journey from Molecule to Marketplace: Strategies for Global Commercialization Success [Lunch in Room]
    Biopharma companies encounter crucial commercial barriers as they navigate their assets from molecule to marketplace. In a contemporary landscape where product types and therapies are diversifying, bi ...
    Super Session
    • Business Development and Investment
    205ABC

    Sponsored by:

    cencora

    Moderator
    Sandra Anderson
    Sandra Anderson, Senior Vice President, Commercialization - Cencora
    Speakers
    Tom Doyle
    Tom Doyle, Head US Commercial Solutions - Cencora
    Alexander Natz
    Alexander Natz, Secretary General - EUCOPE
    Glenn Pauly
    Glenn Pauly, Former Chief Commercial Officer - Former Alzheon
    Kelly Price
    Kelly Price, Managing Director of US Rare Disease - Esteve
  22. Super Session
    Partnering to Accelerate Clinical Breakthroughs: Fireside Chat with Penny Heaton, MD and Nauman Shah [Lunch in Room]
    Join as Johnson & Johnson’s Penny Heaton, MD, Global Head of the Johnson & Johnson Office of the Chief Medical Officer, and Nauman Shah, Global Head of Innovative Medicine Business Development, discus ...
    Super Session 253ABC

    Sponsored by:

    johnson&johnson

    Moderator
    Mandy Jackson
    Mandy Jackson, Managing Editor, US Commercial News - Scrip
    Speakers
    Penny Heaton
    Penny Heaton, Global Head, Office of the Chief Medical Officer - Johnson & Johnson
    Nauman Shah
    Nauman Shah, Global Head of Business Development - Johnson & Johnson
  23. The Disorder Channel Film - Together We Travel: A STXBP1 Journey
    This film follows two families as they begin a clinical drug trial that seems to offer the best hope for their children. Both families connect with the STXBP1 community for guidance and support on the ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Susan Roberts
    Susan Roberts, Founder - Roberts Communications
  24. MilliporeSigma North American Advance Biotech Grant Award Ceremony
    Join us to hear from our finalists and discover who will receive over $250,000 in bioprocessing technologies, bioprocessing consulting services, contract testing services. The next round of applicatio ...
    Start-Up Stadium Session North Lobby
  25. Next-Gen Advocates: Patients & Families Driving Breakthroughs in Rare Disease Drug Development
    This panel will explore the vital role of patients and their families in driving innovation in rare disease therapies. By sharing personal experiences and expert insights, panelists will highlight how ...
    Breakout Session
    • Orphan and Rare Disease
    251
    Moderator
    Lei Lei Wu
    Lei Lei Wu, Reporter - Endpoints News
    Speakers
    Jill Chertow
    Jill Chertow, Founder and President - Propionic Acidemia Foundation
    Wendy Erler
    Wendy Erler, SVP Patient Affairs - Sarepta Therapeutics
    Karin Knobe
    Karin Knobe, Global Head of Rare Diseases Clinical Development - Sanofi
    Julia Vitarello
    Julia Vitarello, Co-founder - EveryONE Medicines
    Michelle Werner
    Michelle Werner, CEO / CEO-Partner - Alltrna / Flagship Pioneering
  26. Undermining Innovation: How Antimicrobial Resistance Imperils Patients and Threatens the Future of Medicine
    Biotechnology companies are producing remarkable therapies at an unprecedented pace. In the past year, two new gene therapies have come to market for patients suffering from sickle cell disease. Rapid ...
    Breakout Session
    • Infectious Disease and Vaccines
    254A
    Moderator
    Henry Skinner
    Henry Skinner, Chief Executive Officer - AMR Action Fund
    Speakers
    Ellen Fraint
    Ellen Fraint, Attending, Pediatric Transplantation and Cellular Therapy - Nemours Children's Health / Nemours Children's Hospital
    Kieren Marr
    Kieren Marr, President and Chief Medical Officer - Elion Therapeutics, Inc.
    Christina Yen
    Christina Yen, Infectious diseases specialist and medical director of antimicrobial stewardship - MaineHealth Maine Medical Center
    Joseph Hammang
    Joseph Hammang, Partner - Vital Transformation, LLC
  27. Computational Drug Design: Benchmarking Bold Bets, Breakthroughs, and Bottlenecks
    This session will explore how investments and bold bets in accelerated computing, data generation at scale, and model-first strategies are revolutionizing the industry, without ignoring the initial ch ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Stacie Calad-Thomson
    Stacie Calad-Thomson, Business Development Lead, Healthcare and Life Sciences, North America - NVIDIA
    Speakers
    Karen Akinsanya
    Karen Akinsanya, President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships - Schrödinger
    Martha Head
    Martha Head, Associate Vice President of the Center for Research Acceleration by Digital Innovation - Amgen
    Najat Khan
    Najat Khan, Chief R&D Officer and Chief Commercial Officer - Recursion
    Derek Lowe
    Derek Lowe, Director in Chemical Biology & Therapeutics - Novartis
    Gregg Talbert
    Gregg Talbert, Senior Vice President, Head of Pharma Transactions and Digital Partnering - Genentech, a member of the Roche Group
  28. Global Puzzle: Decoding Cell Therapy Classifications in Europe and the USA
    The rapid advancement of cell therapies has opened new frontiers in regenerative medicine, but it has also highlighted significant regulatory hurdles across global jurisdictions. One of the most press ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    258A
    Speakers
    Jasmina Savic
    Jasmina Savic, Managing Director - Phortas GmbH
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Eveline Van Keymeulen
    Eveline Van Keymeulen, Partner and Global Vice Chair of the Life Sciences Practice - LATHAM & WATKINS
    Melanie Eacho
    Melanie Eacho, Division Director, CBER - U.S. Food and Drug Administration
  29. Cracking the Code: Effective Biotech and Pharma Partnerships Unveiled
    R&D is often the most cost-intensive and risky step in a new drug's life cycle yet often dictates the speed and adaptability of the innovation ecosystem. The time and capital required for biotech to t ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Hannah Green
    Hannah Green, Life Sciences Reporter - Boston Business Journal
    Speakers
    Lovisa Afzelius
    Lovisa Afzelius, General Partner; Co-Founder and Founding CEO - Flagship Pioneering; Metaphore Biotechnologies
    Ram Aiyar
    Ram Aiyar, Chief Executive Officer and President - Korro Bio, Inc.
    Uli Stilz
    Uli Stilz, Head of the Bio Innovation Hub - Novo Nordisk
  30. Attacking Cancer from All Angles: From ADCs to Immunotherapy
    The cancer therapeutics landscape is constantly evolving as breakthroughs across modalities drive toward the shared goal of providing accessible and life-saving treatments to patients. Companies are a ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Alex Philippidis
    Alex Philippidis, Senior Business Editor - Genetic Engineering & Biotechnology
    Speakers
    Kyle Holen
    Kyle Holen, Head of Development, Therapeutics, and Oncology - Moderna
    Josh Schiffman
    Josh Schiffman, CEO and Co-founder - Peel Therapeutics
    Markus Vallaster
    Markus Vallaster, Global Medical Head, Oncology Early Development & Hemato-Oncology - Astellas
  31. Overcoming Economic Challenges to Rare Disease Drug Development
    The economics of rare-disease research is a consistent obstacle to progress. Although there are more than 10,000 rare diseases that collectively affect over 30 million people in the United States, eac ...
    Breakout Session
    • Orphan and Rare Disease
    206AB
    Moderator
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Patient Advocacy - Biotechnology Innovation Organization (BIO)
    Speakers
    Camilla Graham
    Camilla Graham, Vice President Medical Affairs - PureTech Health
    Christine Swenson
    Christine Swenson, Executive Regulatory Affairs Professional
    Tamar Thompson
    Tamar Thompson, Vice President, Patient Experience & Insights - Alexion, AstraZeneca Rare Disease
  32. Improving and Restoring Vision in Blinding Eye Diseases
    Representatives from biotech, academia, patient advocacy, and the investor community will have a robust and interactive discussion about next generation therapies to treat blinding eye diseases that a ...
    Breakout Session
    • Next Generation Biotherapeutics
    254B
    Moderator
    Jason Menzo
    Jason Menzo, CEO - Foundation for Fighting Blindness
    Speakers
    Paul Bresge
    Paul Bresge, CEO - Ray Therapeutics
    Lance Baldo
    Lance Baldo, CEO - Beacon Therapeutics
    Patrick Ritschel
    Patrick Ritschel, CEO - Atsena Therapeutics
    Arnaud Lacoste
    Arnaud Lacoste, CEO and Chief Scientific Officer - Aurion Biotech
    Samarendra Mohanty
    Samarendra Mohanty, President - Nanoscope Therapeutics Inc
  33. The State of Emerging Biotechs: Investment, Deal, and Pipeline Trends
    This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
    Breakout Session
    • Business Development and Investment
    252AB
    Speakers
    Daniel Chancellor
    Daniel Chancellor, VP, Thought Leadership - Norstella
    Chad Wessel
    Chad Wessel, Director, Industry Analysis - Biotechnology Innovation Organization (BIO)
  34. Fireside Chat
    Fireside Chat with Dr. Feng Zhang, Core Institute Member of the Broad Institute of MIT and Harvard, and Scientific Co-Founder of Moonwalk Biosciences
    Join us for an exclusive fireside chat with Feng Zhang, PhD, renowned scientist and core member of the Broad Institute, an Investigator at the McGovern Institute for Brain Research, the James and Patr ...
    Fireside Chat
    • Next Generation Biotherapeutics
    205ABC
    Moderator
    Alex Aravanis
    Alex Aravanis, CEO & Founder - Moonwalk Biosciences
    Speakers
    Feng Zhang
    Feng Zhang, Feng Zhang is a core institute member of the Broad Institute of MIT and Harvard - Broad Institute of MIT
  35. Student Program: Introduction to Biotechnology
    Whether you're just starting your career or looking to take the next big step, this session will help you navigate the biotech industry. We will begin with an overview of what biotechnology is and its ...
    Student Program 209
    Moderator
    John Newby
    John Newby, CEO - Virginia Biotechnology Association
    Speakers
    Daniel Oliver
    Daniel Oliver, CEO and Co-founder - Rejuvenate Bio
    Jennifer McNary
    Jennifer McNary, Co-founder - Canary Advisors
    Ryan Rust
    Ryan Rust, Senior Director, Business Development - Eli Lilly and Company
    Karin Eisinger
    Karin Eisinger, CEO and co-founder - SyzOnc
  36. Super Session
    Power Partnerships: How Novartis is Revolutionizing Medicine with Biotech, VCs, and Pharma Collaborations
    Strategic partnerships between biotech innovators, VCs and pharmaceutical companies have become the cornerstone of drug development, illustrating a beneficial exchange where cutting-edge research meet ...
    Super Session
    • Business Development and Investment
    253ABC

    Sponsored by:

    novartis

    Moderator
    Michelle Davis
    Michelle Davis, M&A Reporter - Bloomberg News
    Speakers
    Aharon (Ronny) Gal
    Aharon (Ronny) Gal, Chief Strategy & Growth Officer - Novartis
    Alfred Sandrock
    Alfred Sandrock, President and CEO of Voyager Therapeutics - Voyager Therapeutics
    Kevin Bitterman
    Kevin Bitterman, Partner - Atlas Venture
    Bill Muery
    Bill Muery, CEO - Anthos Therapeutics
    Nandita Shangari
    Nandita Shangari, Managing Director - RA Capital
  37. Fireside Chat
    A Conversation with Pennsylvania Governor Josh Shapiro and BIO CEO John F. Crowley on the Importance of Building and Strengthening the Nation’s Bioscience Industry
    Since its founding, Pennsylvania has been a leader in medicine and the life sciences. The first hospital in the United States was established in Philadelphia in 1751 followed by the first school of ph ...
    Fireside Chat
    • Value‚ Patient Access and Reimbursement
    210B
  38. Global Innovation Hub Afternoon Presentations
    Global Innovation Hub Session 152
  39. Rethinking Real-World Data Collection to Improve Patient Outcomes
    Real-world data (RWD) has long informed clinical research, but traditional sources - electronic health records, claims data, registries - often provide only a partial view of patient health. This can ...
    Breakout Session
    • Diagnostics and Personalized Medicine
    208

    Sponsored by:

    evidation

    Moderator
    Joy Eckert
    Joy Eckert, Research Manager - The Reagan-Udall Foundation for the FDA
    Speakers
    Rachel Sha
    Rachel Sha, CEO - Vaxess Technologies, Inc.
    Leslie Wilberforce
    Leslie Wilberforce, CEO - Evidation Health Inc
    Dan Jacob
    Dan Jacob, , Global Head, Real World Evidence, Real World Data, and Behavioral Science - Bayer Consumer Care AG
  40. Start-Up Stadium Tuesday afternoon
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  41. Global Access and Affordability of Biologics
    BioProcess International Theater
    • Biomanufacturing
    Bioprocess Theater
  42. The New Era of Project Optimus: Implications for Oncology Development Strategy
    Initially drafted in January 2023 and finalized in August 2024, the US Food and Drug Administration (FDA) released guidance tied to Project Optimus, titled “Optimizing the Dosage of Human Prescription ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Keya Watkins
    Keya Watkins, Senior VP - Catalyst Oncology
    Speakers
    Gilles Gallant
    Gilles Gallant, Chief Development Officer - Mythic Therapeutics, Inc.
    Andrew Zupnick
    Andrew Zupnick, VP, Oncology Drug Development - Catalyst Oncology
    Dushen Chetty
    Dushen Chetty, Global Head of Oncology & Hematology Development, Ad Interim - Novartis
  43. What are the Opportunities and Challenges for the New Generation of TechBio Partnerships Powered by Generative and Foundational AI?
    Recent Nobel Prizes in deep learning, structure prediction, microRNA, and mRNA signal that the pharmaceutical industry is entering a new era of innovation, driven by the rapid rise of generative and f ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Stacie Calad-Thomson
    Stacie Calad-Thomson, Business Development Lead, Healthcare and Life Sciences, North America - NVIDIA
    Brendan Frey
    Brendan Frey, Founder & Chief Innovation Officer - Deep Genomics
    Chris Hart
    Chris Hart, VP, Data Science and AI/ML, Lilly Institute of Genetic Medicine - Eli Lilly and Company
    Sarah Korman
    Sarah Korman, General Counsel & Head of Business Operations - Isomorphic Labs
  44. Expanding the Reach of Cell Therapies: Shaping the Future of Autoimmune Disease Treatment
    Originally pioneered as lifesaving treatments for patients with cancer, cell therapies have burst onto the biotech scene as promising, disease-eliminating treatments for autoimmune disorders – a notor ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    206AB
    Moderator
    Kara Miller
    Kara Miller, Boston Globe Correspondent - Laurel Way Productions
    Speakers
    Joe Arron
    Joe Arron, Chief Scientific Officer - Sonoma Bio
    Carsten Brunn
    Carsten Brunn, CEO - Cartesian Therapeutics
    Richard Freed
    Richard Freed, CEO and Co-founder - RheumaGen
  45. Inflation Reduction Act (IRA) Litigation: Past and Future Impact on the Price Negotiation Framework
    The legal challenges to the Inflation Reduction Act are now mature. It is critical to assess, at this inflection point, what they have and have not accomplished. As cases move from the District Courts ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    254A
    Moderator
    John Delacourt
    John Delacourt, Deputy General Counsel, VP - Health, Regulatory & Commercial Operations - Biotechnology Innovation Organization (BIO)
    Speakers
    Julia Kiechel
    Julia Kiechel, VP, Commercial Litigation - Johnson & Johnson
    Jeffrey Handwerker
    Jeffrey Handwerker, Partner - Arnold and Porter
    Zachary Baron
    Zachary Baron, Director - Center for Health Policy and the Law, O’Neill Institute, Georgetown Law
  46. An Investor and a Value Assessor Walk into a Bar
    Nearly a quarter of adults in the United States report difficulty affording prescription drugs which is often attributed to the drug’s price set by the manufacturer rather than to the patient out-of-p ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    210A
    Moderator
    Tess Cameron
    Tess Cameron, Principal - RA Capital
    Speakers
    Melanie Whittington
    Melanie Whittington, Managing Director and Head - Leerink Center for Pharmacoeconomics
  47. Unlocking the Future: Opportunities and Challenges in Advanced Biologics Manufacturing
    This panel will explore the opportunities and hurdles in the dynamic field of advanced biologics manufacturing, where innovative technologies intersect with medical advancements. This domain offers si ...
    Breakout Session
    • Biomanufacturing
    209
    Moderator
    Ger Brophy
    Ger Brophy, Chair, Avantor Scientific Advisory Board - Avantor
    Speakers
    Michael Paglia
    Michael Paglia, Chief Technology Officer - ElevateBio
    Stacy Springs
    Stacy Springs, Executive Director - MIT Center for Biomedical Innovation
    Johannes van der Loo
    Johannes van der Loo, Adjunct Associate Professor of Pathology and Laboratory Medicine - University of Pennsylvania's Perelman School of Medicine
    Sergio Cerdas
    Sergio Cerdas, Global Head, Radioligand Therapies (RLT) Manufacturing - Novartis
  48. Beyond the Deal: Navigating Increasingly Complex Collaborations in Pursuit of Innovation
    Partnering with innovative companies at all stages of development is core to how we discover and develop new groundbreaking medicines. Establishing those deep and successful partnerships presents nume ...
    Breakout Session
    • Business Development and Investment
    252AB

    Sponsored by:

    genentech

    Moderator
    Max Bayer
    Max Bayer, Pharma Reporter - Endpoints News
    Speakers
    Beth Odeh-Frikert
    Beth Odeh-Frikert, Head Global Alliance and Asset Management, Corporate Business Development - Genentech, a member of the Roche Group
    Petra Sansom
    Petra Sansom, Vice President, Alliance Management - Beam Therapeutics
    Peggy Taylor
    Peggy Taylor, Vice President, Head of Alliance Management - Alnylam Pharmaceuticals
    Niko Kley
    Niko Kley, Founder, President & CEO - Orionis Biosciences
  49. Maximizing Protection: Enhancing National RSV Infant Immunization Strategies
    The completion of two seasons of RSV immunization for infants provides us with an opportunity to reflect on ways to enhance policies, programs, and systems to maximize protection for infants. Successf ...
    Breakout Session
    • Infectious Disease and Vaccines
    258A

    Sponsored by:

    merck

  50. The Disorder Channel Films
    One Shot to Live - Single-gene therapy may be the greatest hope for thousands of children with rare diseases. But the greatest challenge is time, or the lack of it. The parents of these children fight ...
    Storytelling Stage Storytelling Stage (Booth #349)
  51. Future Horizon – Addressing Disease with Precision Genetic Medicines
    Revolutionary breakthroughs in genetic science have transformed what was once a futuristic approach into an attainable shift in the medical paradigm. Today’s tools enable diagnosis and individualized ...
    Breakout Session
    • Next Generation Biotherapeutics
    254B
    Moderator
    John Schiel
    John Schiel, Program Manager, Scalable Solutions - Advanced Research Projects Agency for Health (ARPA-H)
    Speakers
    Roberta Duncan
    Roberta Duncan, Chief Strategy Officer, Arcturus - Vice Chair, Board, Alliance for mRNA Medicines (AMM)
    Mimi Lee
    Mimi Lee, Program Manager, Health Science Futures - Advanced Research Projects Agency for Health (ARPA-H)
    Tracey Sikora
    Tracey Sikora, Vice President of Research and Clinical Programs - National Organization for Rare Disorders (NORD)
    Tania Simoncelli
    Tania Simoncelli, Vice President of Translational Impact and Engagement - Chan Zuckerberg Initiative (CZI)
  52. Global Biotechnology at a Crossroads: A High-Level Dialogue on Innovation and Changing Trade Dynamics
    Biotechnology is reshaping economies and healthcare systems across the globe, and governments are investing heavily to build national capabilities. Yet at the same time, shifting trade dynamics and ev ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    253ABC
    Moderator
    Phyllis Arthur
    Phyllis Arthur, Executive Vice President & Head of Healthcare Policy and Programs - Biotechnology Innovation Organization (BIO)
    Speakers
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Lord Vallance
    Lord Vallance, UK Minister of State for Science, Research and Innovation
    Darío Genua
    Darío Genua, Secretary of Innovation, Science, and Technology of Argentina
    Javier Dávila
    Javier Dávila, Director General for Planning and Evaluation and Head of the Pharmaceutical Industry and Medical Equipment Division - Ministry of Economy
    His Excellency Prof. Dr. Hisham Saad Aljadhey
    His Excellency Prof. Dr. Hisham Saad Aljadhey, Chief Executive Officer - Saudi Food and Drug Authority (SFDA)
  53. Fireside Chat with Martin A. Makary MD, MPH, Commissioner of Food and Drugs, U.S. Food and Drug Administration
    Dr. Martin Adel Makary, was confirmed on March 25, 2025 by the U.S. Senate as the 27th Commissioner of Food and Drugs. In this role, Dr. Makary oversees the full breadth of the FDA portfolio and execu ...
    Featured Program Main Stage
    Speakers
    Martin Makary
    Martin Makary, Commissioner of Food and Drugs - U.S. Food and Drug Administration
  54. Novel Oncology Targets & Modalities Enter the Clinic - What’s Next?
    According to the most recently available figures, more than 2,000 new oncology clinical trials have begun since 2023, demonstrating the continued need for innovative and effective cancer therapies. Wh ...
    Breakout Session
    • Oncology
    204AB
    Moderator
    Selina Koch
    Selina Koch, Executive Editor, Head of Intelligence & Research - BioCentury Inc.
    Speakers
    Angela Cacace
    Angela Cacace, Chief Scientific Officer - Arvinas
    William Sellers
    William Sellers, Core Institute Member and Cancer Program Director, Broad Institute - Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School
    Scott Armstrong
    Scott Armstrong, Senior Vice President for Drug Discovery & Chief Research Strategy Officer - Dana-Farber Cancer Institute
    Jeevan Virk
    Jeevan Virk, Therapeutic Area Strategy Head - Novartis
    Gromek Smolen
    Gromek Smolen, Vice President, Biology - Foghorn Therapeutics
  55. Unlocking Investment for Women’s Health
    The commitment to women’s health has been increasing over the past year from the US government and dedicated early-stage seed funds. As this funding is deployed to promote innovation and provide solut ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Misti Ushio
    Misti Ushio, Managing Partner - Digitalis Ventures
    Speakers
    Meredith Fisher
    Meredith Fisher, Partner - Mass General Brigham Ventures
    Stacey Seltzer
    Stacey Seltzer, Managing Partner - Pontiva
    Ipsita Smolinski
    Ipsita Smolinski, Founder & Managing Director - Capitol Street
    Megann Vaughn Watters
    Megann Vaughn Watters, Vice President, Corporate Development, New Ventures & Strategic Alliances - Labcorp
  56. Policy Outlook: All Eyes on Intellectual Property Rights
    Intellectual property rights are the bedrock of life-science innovation. But attacks on numerous fronts, from pervasive anti-patent myths to attempts to misuse march-in rights, now threaten to erode t ...
    Breakout Session
    • Intellectual Property and Legal Landscape
    254A
    Moderator
    Sarah Alspach
    Sarah Alspach, Executive Vice President and Chief Communications Officer - Biotechnology Innovation Organization (BIO)
    Speakers
    Joseph Allen
    Joseph Allen, Executive Director - Bayh-Dole Coalition
    John Glasspool
    John Glasspool, CEO - VarmX
    Erika Smith
    Erika Smith, CEO - EpiTET Therapeutics
    Laura Peter
    Laura Peter, Former Deputy Director, USPTO Executive Director, Division of Research - UNC Charlotte
  57. Co-Discovery and Co-Development Partnerships to Accelerate Next-Generation Medicines
    Co-discovery and co-development partnerships have become a cornerstone of the biopharma industry. These partnerships can unlock the potential for groundbreaking medicines, yet their scientific complex ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Jake Beverage
    Jake Beverage, VP, Alliance Management - AbCellera
    Speakers
    Wanda Rutledge-Gordon
    Wanda Rutledge-Gordon, Associate Vice President, Chief Alliance Officer - Eli Lilly
    Risa Shapiro
    Risa Shapiro, Head of Alliance Management for Platforms & Early R&D - Novartis
    Peggy Scherle
    Peggy Scherle, Chief Scientific Officer - Prelude Therapeutics
    Jeremy Ahouse
    Jeremy Ahouse, VP of Alliance Management for Pioneering Medicines - Flagship Pioneering
  58. Bridging the Innovation Valley of Death: A Call for Greater Pharma-Biotech-Academia Collaboration
    Why are so many drug discoveries still failing to make it out of the lab when the speed of, and competition for, innovation has never been higher? Could solving this challenge lie in the unique relati ...
    Breakout Session
    • Translational Research
    208
    Moderator
    Johannes Fruehauf
    Johannes Fruehauf, Founder and Chief Executive Officer - LabCentral / Biolabs
    Speakers
    Eric Kelsic
    Eric Kelsic, CEO & Cofounder - Dyno Therapeutics
    Andrew Mortlock
    Andrew Mortlock, Executive Vice-President, Head of Early Development and Translational Science - Astellas Pharma Inc
    Angela Shen
    Angela Shen, Vice President, Strategic Innovation Leaders, Innovation; Head of Regulatory, Gene and Cell Therapy Institute - Mass General Brigham
    Kirk Taylor
    Kirk Taylor, President and CEO - Massachusetts Life Sciences Center
  59. Innovative Patient-Focused Models for Accelerating Rare Drug Development
    We are witnessing a revolution in rare disease drug development. Traditional models fall short due to small patient populations and limited disease understanding. However, regulatory agencies are now ...
    Breakout Session
    • Orphan and Rare Disease
    254B
    Moderator
    Cara Altimus
    Cara Altimus, Managing Director, Science Philanthropy Accelerator for Research and Collaboration - Milken Institute
    Speakers
    Nasha Fitter
    Nasha Fitter, Co-Founder & Chief Business Officer - Citizen Health
    Sunitha Malepati
    Sunitha Malepati, Founder & CEO/VP - Buffalo Initiative/CACNA1A Foundation
    Nicole Verdun
    Nicole Verdun, Former Super Office Director, CBER - U.S. Food and Drug Administration
    Kemi Olugemo
    Kemi Olugemo, Chief Medical Officer - Korro Bio
  60. Bridging the Biodata Gap: Revolutionizing AI's Impact in Biopharma by Creating ”Digital Twins” of the Natural World
    Biopharma’s ability to create new drugs has depended, from the start, on our collective knowledge of Earth’s genetic biodiversity. While many existing datasets have sought to describe the world, they ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    David Ruau
    David Ruau, Head of Business Development & Strategic Alliances, EMEA Region - NVIDIA
    Speakers
    John Finn
    John Finn, Chief Scientific Officer - Basecamp Research
    Patrick Schwab
    Patrick Schwab, Senior Director of Machine Learning and AI - GSK
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Nicole Rohr
    Nicole Rohr, Associate - Ropes & Gray
  61. Building a Diverse Life Science Workforce for the Nation’s Bioeconomy: Four Industry-Academic Models
    A steady and impressive track record of growth in the life sciences industry has kept access to a skilled, diverse workforce at top of mind for life science leaders, even amid occasional retractions. ...
    Breakout Session
    • Diversity and Opportunity
    209
    Moderator
    Maria Thacker Goethe
    Maria Thacker Goethe, President and CEO - Georgia Life Sciences
    Speakers
    Angie McMurry
    Angie McMurry, Director, Industry Engagement and Workforce - Ohio Life Sciences
    John Newby
    John Newby, CEO - Virginia Biotechnology Association
    Jenae Williams
    Jenae Williams, Director of Workforce and Partnerships - NC Life Sciences Organization
    Danielle Thompson-Reynolds
    Danielle Thompson-Reynolds, Head of Manufacturing Training and Support, Manufacturing Support, MA Bio Ops - Takeda
    Robyn Cardwell
    Robyn Cardwell, Senior Director of Strategic Partnerships - San Jacinto College's Center for Biotechnology
  62. Next-Gen Medicine: How Gene Editing and Epigenetics are Revolutionizing Health, Longevity, and Organ Transplantation
    As gene editing and epigenetics evolve, they are not only transforming how we approach complex diseases but also unlocking new possibilities for enhancing longevity, healthspan, and even organ transpl ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    206AB
    Moderator
    Uduak Thomas
    Uduak Thomas, Senior Editor - Genetic Engineering & Biotechnology News
    Speakers
    Elaine Cheung
    Elaine Cheung, Chief Business Officer - Moonwalk Biosciences
    Daniel Oliver
    Daniel Oliver, CEO and Co-founder - Rejuvenate Bio
    Jim Martineau
    Jim Martineau, CEO & Co-Founder - Nosis Bio
    Wenning Qin
    Wenning Qin, SVP Innovation - eGenesis
    Amber Salzman
    Amber Salzman, CEO - Epicrispr
  63. Super Session
    Partnering for Progress: Exploring Biotech Innovations and Opportunities in Saudi Arabia
    This session will open with an overview of Vision 2030 and explanation of the Kingdom’s commitment to the role of biotech in advancing healthcare. A panel discussion will then explore the key drivers ...
    Super Session 253ABC

    Sponsored by:

    saudi biotech

     

    Moderator
    Ranch Kimball
    Ranch Kimball, Senior Advisor - Boston Consulting Group (BCG)
    Speakers
    H.E. Dr. Majid Al Fayyadh
    H.E. Dr. Majid Al Fayyadh, Chief Executive Officer - King Faisal Specialist Hospital and Research Centre
    Prof. Dr. Hisham Saad AlJadhey
    Prof. Dr. Hisham Saad AlJadhey, Chief Executive Officer - Saudi Food and Drug Authority
    H.E. Dr. Bandar AlKnawy
    H.E. Dr. Bandar AlKnawy, Chief Executive Officer of the Ministry of National Guard Health Affairs (MNGHA) and President - King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), Saudi Arabia
    Prof. Fars Kaed Alanazi
    Prof. Fars Kaed Alanazi, Chief Executive Officer - Saudi National Institute of Health (SNIH)
    H.E. Abdulaziz Hamad Alramaih
    H.E. Abdulaziz Hamad Alramaih, Vice Minister of Health for Planning and Development - Saudi Arabia
    Raid bin Abdullah Ismail
    Raid bin Abdullah Ismail, Senior Director, Co-Head of Direct Investments, & Head of Operation Value Creation MENA Investments Division - Public Investment Fund (PIF)
  64. How To Tell a Story with The Moth [Complimentary Book]
    Storytelling is a powerful way to connect, and a critical skill for leaders and advocates today. The Moth is an acclaimed nonprofit organization dedicated to the art and craft of true, personal storyt ...
    Special Program
    • Special Program
    205ABC
    Speakers
    Larry Rosen
    Larry Rosen - Master Instructor at The Moth
  65. Fireside Chat
    Fireside Chat with the EU Commissioner of Health and Animal Welfare, Olivér Várhelyi
    The biotechnology sector is evolving rapidly, driven by breakthroughs in science, shifts in policy, and growing demand for resilient healthcare systems. In this fireside chat, EU Health and Animal Wel ...
    Fireside Chat
    • Emerging Opportunities in Global Markets
    210B
    Moderator
    Fritz Bittenbender
    Fritz Bittenbender, Senior Vice President - Genentech
    Speakers
    Olivér Várhelyi
    Olivér Várhelyi, European Commissioner for Health and Animal Welfare
  66. Novo Nordisk’s Search, Evaluation and Transactions for Partnerships in Obesity/Diabetes: Discussion on Areas of Interest, Opportunity Assessments, and Governance Processes
    This panel will provide a multidimensional, internal look at how different groups across Novo Nordisk collaborate to expand the options available for improving treatments of obesity and diabetes to he ...
    Breakout Session
    • Business Development and Investment
    258A

    Sponsored by:

    novo nordisk

    Moderator
    Tomas Landh
    Tomas Landh, Strategic Enterprise Strategy Expert Global Search & Evaluation - Novo Nordisk
    Speakers
    Tari Suprapto
    Tari Suprapto, Senior Director and Head of Global Innovation Sourcing - Novo Nordisk
    Tamara Darsow
    Tamara Darsow, Senior Vice President, Corporate Development - Novo Nordisk
    John McDonald
    John McDonald, Corporate Vice President - Novo Nordisk
    Kasper Veje
    Kasper Veje, Vice President, Head of Diabetes & Obesity Search and Evaluation - Novo Nordisk
  67. Discussing the Future of Biotech: Innovation, Sustainability, and Growth in a Dynamic Landscape
    This session explores the cutting-edge trends and strategic decisions transforming the modern biotech industry. Our expert panelists will dive into the most impactful technological innovations in larg ...
    Breakout Session
    • Biomanufacturing
    251

    Sponsored by:

    thermofisher scientific

    Moderator
    Ben Castro
    Ben Castro, Vice President/General Manager, Large Molecule - Thermo Fisher Scientific
    Speakers
    Stephen Grant
    Stephen Grant, Industry Executive/Fractional COO and Angel Investor
    Chuck Hart
    Chuck Hart, Founder/Owner - HartEdge BioOps Consulting LLC
    Parika Petaipimol
    Parika Petaipimol, Vice President of Technical Operations - Upstream Bio
    Brian Tham
    Brian Tham, Principal Consultant - Peregrine Bio, LLC
3:30 PM (ET)
  1. Fueling Innovation: Strategies for Funding Academic Spin Outs
    Biotech startups emerging from universities are at the forefront of innovation, pushing the boundaries of science and medicine. However, translating groundbreaking research into viable commercial prod ...
    Breakout Session
    • Translational Research
    204AB
    Moderator
    Lisa Mueller
    Lisa Mueller, Ms - Casimir Jones
    Speakers
    Nichole Mercier
    Nichole Mercier, Assistant Vice Chancellor and Managing Director (WashU); President and Co-Founder (Equalize Inc) - Washington University in St. Louis
    Mike Partsch
    Mike Partsch, Chief Venture Officer - Wisconsin Alumni Research Foundation (WARF)
    Marc Sedam
    Marc Sedam, Vice President, Technology Opportunities & Ventures - NYU Langone Health
    Simon Warner
    Simon Warner, Head of Licensing and Ventures - Oxford University Innovation
  2. Trusting the Machines: Designing Transparent AI Solutions for Healthcare
    As AI becomes integral to healthcare, ensuring transparency and trust through regulatory compliance is critical. Multi-agent systems, where different AI agents specialize in distinct tasks, are gainin ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Paul Howard
    Paul Howard, Executive Director, Policy and Patient Experience Innovation - Amicus Therapeutics
    Speakers
    Erik Huestis
    Erik Huestis, Partner - Foley Hoag
    Mida Pezeshkian
    Mida Pezeshkian, Founder, Principal - Stema-Cg
    Vangelis Vergetis
    Vangelis Vergetis, Co-founder - Epikast
    Michael Patriarca
    Michael Patriarca, Vice President and Chief Business Officer - Tulane University School of Medicine
  3. What Investors/Strategic Partners Want in 2025: Building Presentations for Success
    Back by popular demand, this high-impact session returns to BIO and will guide health and science executives through a proprietary framework developed by LaVoieHealthScience: The LHS Fifteen-Slide Pre ...
    Breakout Session
    • Business Development and Investment
    252AB
    Speakers
    Donna LaVoie
    Donna LaVoie, Founder & CEO - LaVoieHealthScience
    Elise Simard
    Elise Simard, President - SpeechComm, Inc.
  4. Platform Power: How Genetic Medicine Technologies are Changing Expectations for Medicine
    The Human Genome Project led to an explosion of knowledge about the genetic roots of disease. Now leaders in genetic medicine technologies, including RNAi therapeutics and CRISPR gene editing, are har ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    251
    Moderator
    Ryan Cross
    Ryan Cross, Senior Science Correspondent - Endpoints News
    Speakers
    Christos Kyratsous
    Christos Kyratsous, Senior Vice President, Research and Co-Head, Regeneron Genetic Medicines - Regeneron
    Laura Sepp-Lorenzino
    Laura Sepp-Lorenzino, Board Member, Scientific Advisor, and former Chief Scientific Officer - Intellia Therapeutics
    Paul Nioi
    Paul Nioi, Senior Vice President of Research - Alnylam Pharmaceuticals
    Akin Akinc
    Akin Akinc, CEO - Aera Therapeutics
  5. The New Era of Mega Blockbusters: Advancing Drug Development for Broader Patient Impact
    Biotech is entering a new era of mega blockbusters - drugs with peak sales potential exceeding $10 billion. Drug developers are increasingly focusing on novel therapies that can reach the largest poss ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Jonathan Norris
    Jonathan Norris, Managing Director - HSBC Innovation
    Speakers
    Omar Khalil
    Omar Khalil, Managing Director - Santé Ventures
    Abbas Kazimi
    Abbas Kazimi, Chief Executive Officer - Nimbus Therapeutics
    Sarah Kilpatrick
    Sarah Kilpatrick, Vice President of Business Development for Pfizer R&D and Pfizer Internal Medicine - Pfizer
    Lizabeth Leveille
    Lizabeth Leveille, Vice President, BD&L - Merck
  6. Weight Loss for Longevity? How Metabolic Drugs are Disrupting Chronic Disease and Improving Healthspan
    The tremendous success of GLP-1/GIP receptor agonists has ushered in a rapid paradigm shift in how we consider and treat chronic metabolic diseases, like obesity and associated comorbidities. These th ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Mia de Graaf
    Mia de Graaf, Deputy Executive Health Editor - Business Insider
    Speakers
    Kristen Fortney
    Kristen Fortney, CEO and Co-Founder - BioAge Labs
    Maha Radhakrishnan
    Maha Radhakrishnan, Executive Partner, Private Equity - Sofinnova Investments
    Hanadie Yousef
    Hanadie Yousef, CEO and Co-Founder - Juvena Therapeutics
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Greg Wiederrecht
    Greg Wiederrecht, Managing Director, Healthcare Investment Banking - Royal Bank of Canada
  7. In Pursuit of Health Equity: How Industry Has Evolved Its Focus On This Critical Healthcare Challenge
    Join us for a dynamic panel discussion exploring the evolution of investment in medical and healthcare interventions designed to advance health equity. In a competitive market, focus on equity during ...
    Breakout Session
    • Diversity and Opportunity
    208
    Moderator
    Tanisha Sullivan
    Tanisha Sullivan, Head, External Engagement & Health Equity Strategy - Sanofi
    Speakers
    Jeff Raphael
    Jeff Raphael, Managing Partner, Life Sciences Strategic Advisory - OmniScope Partners
    Nabiha Saklayen
    Nabiha Saklayen, Co-Founder & CEO - Cellino
    Rodney Cotton
    Rodney Cotton, Venture Partner - 2Flo Ventures
    Tia Lyles-Williams
    Tia Lyles-Williams, Chief Executive Officer - HelaPlex Co.
  8. Delivering to the 80%: Scaling Community-Level CAR-T Access
    While CAR-T therapies have revolutionized cancer treatment, access remains largely confined to major academic medical centers, limiting treatment availability for most eligible patients. Expanding del ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    254B
    Moderator
    Sharon King
    Sharon King, Board Member, Emily Whitehead Foundation - Manager, Advocacy and Community Engagement, Aldevron
    Speakers
    Lynelle Hoch
    Lynelle Hoch, President, Cell Therapy Organization - Bristol Myers Squibb
    Gary Simmons
    Gary Simmons, Medical Doctor - Virginia Oncology Associates
    Tim Hunt
    Tim Hunt, Chief Executive Officer - Alliance for Regenerative Medicine (ARM) 
  9. Aligning Policies Impacting Drug Development with Unmet Patient Need
    Where there is unmet clinical need, opportunities to develop therapeutics to help the greatest number of patients follow. It is important that the surrounding ecosystem directs biopharmaceutical compa ...
    Breakout Session
    • Patient Advocacy
    254A

    Sponsored by:

    astrazeneca

    Moderator
    Steve Usdin
    Steve Usdin, Washington Editor & Head of Policy & Regulation - BioCentury
    Speakers
    Russ Paulsen
    Russ Paulsen, Chief Operating Officer - UsAgainstAlzheimer’s
    Lisa Schlager
    Lisa Schlager, Vice President, Public Policy - FORCE
    John Stanford
    John Stanford, Executive Director - Incubate Coalition
    Paul Hueseman
    Paul Hueseman, Senior Director, Clinical Value & Outcomes, Payer Accounts - AstraZeneca
  10. Optimizing Your Clinical Program Outcomes: Creating an Evidence Based Value Proposition for Commercial Success
    In today’s world, successful therapeutic developers must not only generate clinical data to meet regulatory requirements for approval, they must also demonstrate the value of therapeutic candidates to ...
    Breakout Session
    • Business Development and Investment
    258A

    Sponsored by:

    fortrea

  11. Fireside Chat
    Humanity and Medicine: A Father's Perspective - Fireside Chat with James G. Robinson, author of "More Than We Expected"
    Join BIO's Chief Patient Advocate and Head of the Patient Advocacy Center of Excellence, Michele Oshman, for a fireside chat with author of "More Than We Expected: Five Years With a Remarkable Child", ...
    Fireside Chat
    • Patient Advocacy
    205ABC
    Moderator
    Michele Oshman
    Michele Oshman, Chief Patient Advocate and Head, Patient Advocacy Center of Excellence - Biotechnology Innovation Organization (BIO)
  12. Company Presentations
    Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  13. Incorporating new technologies in development and production, regulatory landscapes, and agile manufacturing
    BioProcess International Theater
    • Biomanufacturing
    Bioprocess Theater
  14. Voices from Biotech
    The BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Susan Roberts
    Susan Roberts, Founder - Roberts Communications
    Speakers
    Natalie Kuldell
    Natalie Kuldell, Executive Director - BioBuilder Educational Foundation
  15. The EU Policy Evolution and Revolution for Biotech
    The EU is reshaping its biotechnology landscape, with the focus on competitiveness, supply and capacity resilience and societal benefit. A European Commission 5 year mandate has over 20 legislations a ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    210B
    Speakers
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Alexander Natz
    Alexander Natz, Secretary General - EUCOPE
  16. Fireside Chat
    Charting the Future of Biotechnology with the U.S. National Security Commission on Emerging Biotechnology
    In 2022, Congress tasked the National Security Commission on Emerging Biotechnology with assessing how the United States can maintain its global lead in biotech and safeguard our collective security. ...
    Fireside Chat
    • Business Development and Investment
    209
    Speakers
    Angela Belcher
    Angela Belcher, Commissioner - National Security Commission on Emerging Biotechnology
    Michelle Rozo
    Michelle Rozo, Vice Chair - National Security Commission on Emerging Biotechnology
  17. Storytelling Stage
    The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #349)
  18. Start-Up Stadium Wednesday morning
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  19. Copays Kill: How Cost Sharing Undermines Health
    This session will discuss why, contrary to conventional wisdom, the need for co-pay and premium assistance, in this complicated environment, is likely to increase, not decrease, under the IRA. Panelis ...
    Breakout Session
    • Patient Advocacy
    254A
    Moderator
    Ashira Vantrees
    Ashira Vantrees, Director of Legal Strategy and Advocacy - Aimed Alliance
    Speakers
    William Sarraille
    William Sarraille, Professor of Practice - University of Maryland Francis King Carey School of Law
    Carl Schmid
    Carl Schmid, Executive Director - Hepatitis + HIV Policy Institute
    Kim Czubaruk
    Kim Czubaruk, Vice President of Policy - CancerCare
  20. Rescuing Promising but Shelved Assets: New Models to Overcome Barriers and Put Unmet Patient Needs First
    Countless preclinical- and clinical-stage drugs remain shelved, not for scientific reasons or because they lack demonstrated potential to help patients, but rather because of strategic, organizational ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Michael Gladstone
    Michael Gladstone, Partner - Atlas Venture
    Speakers
    Annette Bakker
    Annette Bakker, CEO - Children's Tumor Foundation
    Samuel Blackman
    Samuel Blackman, Founder and Strategic Advisor - Day One Biopharmaceuticals
    Uche Iloeje
    Uche Iloeje, Senior Vice President, and Head Global Medical Affairs - SpringWorks Therapeutics
    Brent Kreider
    Brent Kreider, President - Biomed Valley Discoveries
  21. Beyond Bispecifics and ADCs: Conditionally Active Biologics
    A new class of conditionally active biologics that is safer and less toxic than existing therapies is emerging. These drugs have the potential to overcome shortcomings of current state-of-the-art ther ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Michael Rice
    Michael Rice, Expert Advisor, SPV, Cell and Gene Therapy - Lumanity Inc.
    Speakers
    Alexandra Cantley
    Alexandra Cantley, Partner - Polaris Partners
    Stephen Demarest
    Stephen Demarest, Chief Scientific Officer - Tentarix Biotherapeutics Inc.
    Randi Isaacs
    Randi Isaacs, Chief Medical Officer - Werewolf Therapeutics Inc.
    Neela Patel
    Neela Patel, Chief Business Officer - Bonum Therapeutics Inc.
    John Lin
    John Lin, SVP, Immune Oncology, Head of Biospecific R&D - Regeneron Pharmaceuticals
  22. Trends in Dealmaking: Shaping Drug Development Through External Innovation
    Emerging modalities are driving the future of the biopharma industry, and pharmaceutical companies are increasingly turning to external sources for these innovations. This panel brings together speake ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Murray McCutcheon
    Murray McCutcheon, Senior Vice President, Partnering - AbCellera
    Speakers
    Lizabeth Leveille
    Lizabeth Leveille, Vice President, BD&L - Merck
    Michal Preminger
    Michal Preminger, Biotech Innovation Leader
    Paul Thibodeau
    Paul Thibodeau, Global Head, Search & Evaluation, Corporate & Business Development - Novartis
    Tomohiro Yamauchi
    Tomohiro Yamauchi, Executive Director, Global Head of Scouting & Transaction Oncology, Business Development - Astellas Pharma
  23. What If? Preparing for Cybersecurity Risks Begins by Understanding AI’s Role in Attacks and Defense
    The industry is still grappling with GenAI while quantum is lurking around the corner. There are already companies and countries experimenting with quantum. From a business perspective, the ways that ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Lori Ellis
    Lori Ellis, Head of Insights - BioSpace
    Speakers
    Jay Ferro
    Jay Ferro, EVP, Chief Information, Technology, and Product Officer - Clario
    Chris Hart
    Chris Hart, Partner - Foley Hoag
    Mike Walker
    Mike Walker, Executive Director, Global Healthcare and Life Sciences Digital Strategy - Microsoft
    Andrew Griffin
    Andrew Griffin, VP, Global Chief Information Security Officer - Charles River Laboratories
    Greg Singleton
    Greg Singleton, Former Chief AI Officer - U.S. Department of Health & Human Services
  24. Revolutionizing Drug Development: Harnessing New Approach Methodologies (NAMs) for a Safer Future in Medicine
    New Approach Methodologies (NAMs) are at the forefront of transforming how biomedical research translates into real-world treatments, enabling faster and more precise drug development by, in some case ...
    Breakout Session
    • Translational Research
    204AB
    Moderator
    Carmen Laplaza-Santos
    Carmen Laplaza-Santos, Head of Unit Health Innovations and Ecosystems in Directorate General on Research and Innovation - European Commission
    Speakers
    Falk Ehmann
    Falk Ehmann, Head of Innovation and Development Accelerator - European Medicines Agency
    Gerd Kullak-Ublick
    Gerd Kullak-Ublick, Global Head, Mechanistic Safety and Safety Signal Management Patient Safety & Pharmacovigilance - Novartis
    Kylie Sproston
    Kylie Sproston, Chief Executive Officer - Bellberry Limited
    Karissa Adkins
    Karissa Adkins, Head of Global Investigative Toxicology - Sanofi
    Tracy Beth Høeg
    Tracy Beth Høeg, Senior Advisor for Clinical Sciences in the Office of the Commissioner and the Center for Biologics Evaluation and Research (CBER) - U.S. Food and Drug Administration
    Stacey Adam
    Stacey Adam, Vice President of Science Partnerships - FNIH
  25. Reimbursement Innovation: Unlocking the Future of Advanced Therapy Access
    CAR-T and other advanced therapies hold transformative, and even curative potential, however reimbursement bottlenecks are preventing widespread access. Payer hesitation, regulatory complexity, and ot ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    254B
    Moderator
    George Eastwood
    George Eastwood, Executive Director - The Emily Whitehead Foundation
    Speakers
    Kamal Menghrajani
    Kamal Menghrajani, Former Assistant Director, Office of Science and Technology Policy - The White House
    Michael Sherman
    Michael Sherman, Principal, Sherman Healthcare Solutions, LLC - Advisor, RA Capital Management; Former Health Plan CMO
    William Shrank
    William Shrank, Venture Partner - Andreessen Horowitz (A16Z)
  26. Advancing Rare Disease: Strategic Innovations and Collaborative Efforts - Fireside Chat with Amy Comstock Rick, FDA Rare Disease Innovation Hub Director
    The Rare Disease Innovation Hub, established by the FDA in 2024, serves as a pivotal point of collaboration between the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Eval ...
    Breakout Session
    • Orphan and Rare Disease
    258A
    Moderator
    Libby Barksdale
    Libby Barksdale, Senior Director, Science and Regulatory Affairs - Biotechnology Innovation Organization (BIO)
    Speakers
    Amy Comstock Rick
    Amy Comstock Rick, Director of Strategic Coalitions, Rare Disease Innovation Hub - U.S. Food and Drug Administration
  27. From Clinical to Commercial: How Strategic Partnerships Can Accelerate Development and Enable Launch Excellence
    In the rapidly evolving landscape of cell and gene therapy, the journey from clinical development to commercial launch presents unique challenges and opportunities. This session will provide attendees ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    251

    Sponsored by:

    cencora

    Moderator
    Kevin Chinn
    Kevin Chinn, Vice President and Head of the Cell & Gene Therapy Service Line - Cencora
    Speakers
    Brad Martin
    Brad Martin, Vice President, Head of Market Access and Trade - Neurotech Pharmaceuticals
    Mathias Kroll
    Mathias Kroll, Chief Business Officer - Cynata
    Sare Largay
    Sare Largay, Chief Officer Biomedicine North America - Miltenyi
    Laurel Todd
    Laurel Todd, VP, US Market Access & Policy - Iovance
  28. Ensuring Food Security to Optimize Chronic Medical Condition Care
    Food is medicine—and yet, for millions, it’s out of reach. Since 2021, the Greater Boston Food Bank has led the way and conducted an annual survey of Massachusetts households to determine the rates an ...
    Special Program
    • Patient Advocacy
    253ABC
    Moderator
    Brooke Sutherland
    Brooke Sutherland, Boston Bureau Chief - Bloomberg
    Speakers
    Lauren Fiechtner
    Lauren Fiechtner, Director, Center for Pediatric Nutrition, Mass General Hospital for Children - Assistant Professor, Harvard Medical School
    Diana Gallagher
    Diana Gallagher, Head of Alzheimer’s and Dementia Development Unit & Head, MS and Immunology Development Unit - Biogen
    Christina Economos
    Christina Economos, Dean, Professor, New Balance Chair in Childhood Nutrition - Friedman School of Nutrition Science and Policy, Tufts University
    Pablo Buitron de la Vega
    Pablo Buitron de la Vega, Assistant Professor of Medicine, General Internal Medicine - Boston University Chobanian and Avedisian School of Medicine
  29. The Next Frontier: How Stories Can Unlock the Power of Biotech
    “The Next Frontier,” a new branded film series produced by BBC StoryWorks and presented by BIO, explores how biotechnology is shaping the future of health, climate, and food, but if public understandi ...
    Special Program
    • Next Generation Biotherapeutics
    205ABC
    Moderator
    Sarah Alspach
    Sarah Alspach, Executive Vice President and Chief Communications Officer - Biotechnology Innovation Organization (BIO)
    Speakers
    Lucia Contofalska
    Lucia Contofalska, Manager, Patient Advocacy - Chiesi Global Rare Diseases
    Christine Mackay
    Christine Mackay, Community & Economic Development Director - City of Phoenix
    Pam Mangat
    Pam Mangat, Head of Creative - BBC StoryWorks Commercial Productions
    Daniel Wee
    Daniel Wee, Chief eXecution Officer - Enveda
  30. Structuring Partnerships for Success in Vaccine Development
    What makes a partnership work in vaccine development? When is it the right stage to partner programs? How do you identify strategic partner fits? With its own unique ecosystem, vaccine development and ...
    Breakout Session
    • Infectious Disease and Vaccines
    210B

    Sponsored by:

    novavax

    Moderator
    Max Bayer
    Max Bayer, Pharma Reporter - Endpoints News
  31. Book Signing with James G. Robinson, author of "More than We Expected" [Complimentary Book]
    Following his fireside chat, join James Robinson for a book signing and meet and greet. Complimentary copies of the books will be available at the signing on a first come, first served basis. Book sig ...
    Special Program
    • Patient Advocacy
    NW Lobby
  32. How to Mobilize the Private Sector to Scale U.S. Biotechnology Products?
    This interactive session is designed to provide students with the guidance and connections needed to navigate entry into the biotech industry. Panelists will share their personal career journeys and i ...
    Special Program
    • Business Development and Investment
    209
    Moderator
    Kelly Seagraves
    Kelly Seagraves, Vice President, National Security & International Affairs - Biotechnology Innovation Organization (BIO)
    Speakers
    Luciana Borio
    Luciana Borio, Senior Fellow for Global Health - Council on Foreign Relations
    David Schaffer
    David Schaffer, Director, Bakar Labs & QB3 - Professor of Chemical & Biomolecular Engineering, UC Berkeley
    Joe Buccina
    Joe Buccina, Policy and Research Director - National Security Commission on Emerging Biotechnology (NSCEB)
    Tom DiLenge
    Tom DiLenge, Senior Partner, Global Public Policy, Regulatory & Governmental Strategy - Flagship Pioneering
  33. Planning for the Future: Workforce, Leadership, and Health Outcomes in a Changing Environment
    Legal challenges, directives from elected and appointed leaders, and public funding reductions have intensified in recent months. How do companies remain compliant and committed to their missions? Wha ...
    Breakout Session
    • Diversity and Opportunity
    208
    Moderator
    Ted Love
    Ted Love, Chair - BIO Board of Directors
    Speakers
    Carolina Alarco
    Carolina Alarco, Co-Founder & Co-Chair - Latinos in Bio
    Rob Perez
    Rob Perez, Senior Advisor - General Atlantic
    Michael Samar
    Michael Samar, Chief Financial Officer - Noema Pharma
    Arun Skaria
    Arun Skaria, Head of DEI and Corporate Responsibility - Alnylam
    Charlotte Jones-Burton
    Charlotte Jones-Burton, Founder - WOCIP
  34. Super Session
    Driving Global Growth in Life Sciences: Fireside Chat with Mina Makar, RPh, Senior Vice President, Global Cardiovascular, Renal and Metabolism, AstraZeneca [Lunch in Room]
    Join Anjalee Khemlani (Yahoo Finance) in conversation with Mina Makar, RpH (SVP, Global Cardiovascular, Renal and Metabolism, BioPharmaceuticals Business Unit, AstraZeneca) as they explore the transfo ...
    Super Session
    • Special Program
    205ABC

    Sponsored by:

    astrazeneca

  35. BBC StoryWorks: “The Next Frontier” Films
    The Next Frontier Films: From pandemic preparedness to food security, climate change to resource scarcity, the world requires innovative solutions to the challenges facing society. With its potential ...
    Storytelling Stage Storytelling Stage (Booth #349)
  36. Emerging Modalities
    BioProcess International Theater
    • Biomanufacturing
    Bioprocess Theater
  37. The Disorder Channel Film - RARE HUMANS: Turning Hope into Action
    Eight rare disease families are changing the future of medicine as they pursue their missions to cure the incurable. These inspiring stories of love, loss and determination prove that every one of us ...
    Storytelling Stage Storytelling Stage (Booth #349)
    Moderator
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Patient Advocacy - Biotechnology Innovation Organization (BIO)
  38. Start-Up Stadium Wednesday afternoon
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  39. 35th Biotech Beyond Borders Report: Are Capital Markets Finally Coming Back?
    The 35th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotechnology industry’s standing within a quickly evolving transaction and financing envi ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Arda Ural
    Arda Ural, Americas Life Sciences Leader - EY
    Speakers
    Marian Nakada
    Marian Nakada, VP Venture Investments - Johnson & Johnson Innovation - JJDC
    Paris Panayiotopoulos
    Paris Panayiotopoulos, Senior Managing Director - Blackstone Life Sciences Group
    Greg Verdine
    Greg Verdine, President, Chief Executive Officer, and Board Member - LifeMine Therapeutics
    Ryan MacDonald
    Ryan MacDonald, Vice President, Corporate Development - Bristol Myers Squibb
  40. Achieving Synergy: A Roadmap to Successful Academia-Industry Collaborations from Discussion to Implementation
    Establishing university-industry partnerships enables the realization of ideas and discoveries to become actual products and services that benefit the public. These partnerships present a variety of o ...
    Breakout Session
    • Translational Research
    204AB
    Moderator
    Ed Pagani
    Ed Pagani, Assistant Vice President for External Partnerships - Duke University Office for External Partnerships
    Speakers
    Douglas Krafte
    Douglas Krafte, Chief Scientific Officer - Niroda Therapeutics
    Caroline Lowenthal
    Caroline Lowenthal, Alliance Manager - MIT
    Reed Sprague
    Reed Sprague, Executive Director, Stanford Medicine Industry Relations - Stanford Medicine
    Tari Suprapto
    Tari Suprapto, Senior Director and Head of Global Innovation Sourcing - Novo Nordisk
    Walter David
    Walter David, Director, Research Business Development - City of Hope
  41. The Role of Small Investors in the Biotech Funding Landscape – a Global Perspective
    Hear a diverse panel of small investors (angels and small VCs) from around the world discuss the role of smaller investors in the lifecycle of biotechnology startup companies – both in the US and over ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Yaniv Sneor
    Yaniv Sneor, Founder - Mid Atlantic Bio Angels
    Speakers
    Milla Koistinaho
    Milla Koistinaho, Founding Partner - Innovestor Life Science Fund
    Rob McInnes
    Rob McInnes, Lead, Life Sciences - Sydney Angels - Sydney Angels
    Takehiko Sawabe
    Takehiko Sawabe, Director - Beyond Next Ventures
  42. Celebrating Women Leading Innovation in Biopharma
    Recent data reveals that less than 10% of CEOs in the biopharma industry are women, while female representation in leadership teams stands at 25%. However, the momentum for change is undeniable. A gro ...
    Breakout Session
    • Diversity and Opportunity
    208
    Moderator
    Nicole DeFeudis
    Nicole DeFeudis, Editor - Endpoints News
    Speakers
    Judy Chou
    Judy Chou, President and CEO - AltruBio
    Sabrina Johnson
    Sabrina Johnson, President and CEO - Daré Bioscience
    Angela Hwang
    Angela Hwang, CEO - Metaphore Biotechnologies
    Daisy Robinton
    Daisy Robinton, Co-Founder & CEO - Oviva Therapeutics
    Elizabeth Jeffords
    Elizabeth Jeffords, President & CEO - Iolyx Therapeutics
  43. Ethical and Practical Considerations for Multi-National Rare Disease Clinical Trials
    Conducting multi-national clinical trials for rare diseases poses ethical and logistical challenges, particularly in ensuring equitable patient access and sustainable commercialization plans. This pan ...
    Breakout Session
    • Orphan and Rare Disease
    254B
    Moderator
    Marshall Summar
    Marshall Summar, CEO - Uncommon Cures
    Speakers
    Gareth Baynam
    Gareth Baynam, Medical Director - Rare Care Centre
    Juan Francisco Cabello
    Juan Francisco Cabello, Senior Vice President for Latin America - Uncommon Cures
    Johann de Bruyn
    Johann de Bruyn, CEO - TASK Clinical Trials
    Mohamed Mostafa
    Mohamed Mostafa, Chief Executive Officer - PDC-CRO
  44. Companies Should Embrace RWE Strategies Early and Often
    Integrating real-world evidence (RWE) strategies during drug development and commercialization is critical to maximizing shareholder and stakeholder value. Biopharma executives need to know how to lev ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Susan Nemetz
    Susan Nemetz, Founder and CEO - The NemetzGroup and Corval
    Speakers
    Raymond Mankoski
    Raymond Mankoski, Senior Medical Consultant - The NemetzGroup LLC
    Ruth Pulikottil Jacob
    Ruth Pulikottil Jacob, EMEA HEOR Lead - Cepheid Danaher Company
    Mei Sheng Duh
    Mei Sheng Duh, Managing Partner and Chief Epidemiologist, RPh, MPH, ScD - Analysis Group
    Sara Silacci
    Sara Silacci, Founder and Managing Member - 4Mission Ventures
  45. In Vivo CARs: Unlocking the Potential of Immune Cell Programming in Oncology and Beyond
    In vivo CAR (Chimeric Antigen Receptor) therapies are poised to revolutionize immunotherapy by moving beyond the limitations of traditional ex vivo approaches. These therapies involve programming immu ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Geulah Livshits
    Geulah Livshits, Senior Research Analyst & Managing Director - Chardan
    Speakers
    Kevin Friedman
    Kevin Friedman, Chief Executive Officer - Kelonia Therapeutics
    Daniel Getts
    Daniel Getts, Chief Executive Officer - Myeloid Therapeutics
    Phil Johnson
    Phil Johnson, Chief Executive Officer - Interius BioTherapeutics
    Adrian Bot
    Adrian Bot, Chief Scientific Officer - Capstan Therapeutics
    Ryan Crisman
    Ryan Crisman, CTO - Umoja Biopharma, Inc.
  46. Recognizing the Why Behind Our Medicines: Patient Connection as a Motivator for Impact
    Biotech goes beyond science - although the building blocks of our industry are made up of groundbreaking approaches that start in the lab, the goal is that they end in one place - impacting patients. ...
    Breakout Session
    • Patient Advocacy
    254A
    Moderator
    Michele Oshman
    Michele Oshman, Chief Patient Advocate and Head, Patient Advocacy Center of Excellence - Biotechnology Innovation Organization (BIO)
    Speakers
    Samuel Blackman
    Samuel Blackman, Founder and Strategic Advisor - Day One Biopharmaceuticals
    Rich Brennan
    Rich Brennan, Vice President, Federal Affairs - The ALS Association
    Sean Holleran
    Sean Holleran, Chief Executive Officer - Make-A-Wish Massachusetts and Rhode Island
    Lianna Orlando
    Lianna Orlando, Vice President of Research and Partner, CureDuchenne Ventures - CureDuchenne
    Leslie Williams
    Leslie Williams, Co-Founder, President and CEO - HC Bioscience
  47. Student Program: Breaking into Biotech
    This interactive session is designed to provide students with the guidance and connections needed to navigate entry into the biotech industry. Panelists will share their personal career journeys and i ...
    Student Program 209
    Moderator
    Leah Lindsay
    Leah Lindsay, Lead, R&D Science Philanthropy and Community Engagement - Takeda Pharmaceuticals
    Speakers
    Wyatt McDonnell
    Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Rose Blackburne
    Rose Blackburne, Vice President, Global Head of Population Science Strategies and Women’s Health - Thermo Fisher Scientific
    Stacey Hawkins
    Stacey Hawkins, Founder and CEO - BioTech Primer, Inc
    Natalie Kuldell
    Natalie Kuldell, Executive Director - BioBuilder Educational Foundation
    Jeffrey Herrera
    Jeffrey Herrera, Associate Director, Employee Experience and DEI - Vir Biotechnology, Inc.
  48. Super Session
    Vital Signs: Disruptive Challenges Facing CDMOs and Strategies to Overcome Them
    CDMOs play a pivotal role in the rapidly evolving landscape of the pharmaceutical and biotechnology industries, helping them bring innovative therapies and life-saving products to market. Over the nex ...
    Super Session
    • Special Program
    205ABC

    Sponsored by:

    alixpartners

  49. How Could "Grand Challenges" Investments Solve the Hardest Problems in Biotechnology?
    Breakthroughs in biomanufacturing, biochemical modeling, and AI-enabled drug discovery and development could dramatically boost industry-wide productivity—but they require massive early-stage investme ...
    Special Program
    • Biomanufacturing
    210B
    Moderator
    Kelly Seagraves
    Kelly Seagraves, Vice President, National Security & International Affairs - Biotechnology Innovation Organization (BIO)
    Speakers
    Gevorg Grigoryan
    Gevorg Grigoryan, Co-Founder & Chief Technology Officer - Generate:Biomedicines
    Rhys Dubin
    Rhys Dubin, Policy Advisor, Office of the Special Envoy for Critical and Emerging Technology (S/TECH) - U.S. Department of State
    Steven Moss
    Steven Moss, Senior Policy Advisor - National Security Commission on Emerging Biotechnology (NSCEB)
    J. Christopher Love
    J. Christopher Love, Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering - Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
  50. Building Resilient Global and National Supply Chains
    Biotechnology supply chains are inherently global, spanning research, development, manufacturing, distribution, and skilled workforce networks across multiple countries. This interdependence has drive ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    251
    Speakers
    Rory Mullen
    Rory Mullen, Head of Biopharma and Food - IDA Ireland
    K.Anand Kumar
    K.Anand Kumar, Managing Director - Indian Immunologicals Ltd
    Hilary Stiss
    Hilary Stiss, Senior Director of International Affairs - Biotechnology Innovation Organization (BIO)
  51. Commercializing SBIR/STTR Technologies
    Won an SBIR/STTR grant from the NIH for your biomedical innovation? A new paradigm for inter-agency, industry, and venture capital collaboration is here to help commercialize it! Startups are 50% more ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Rupak Doshi
    Rupak Doshi, CEO - OmniSync Incorporated
    Speakers
    Jain Krotz
    Jain Krotz, Acting Director, Partnerships & Engagement Lead, Innovation and Commercialization Office - The National Heart Lung and Blood Institute
    Prathamesh Prabhudesai
    Prathamesh Prabhudesai, CEO and Co-Founder - SafeBVM Corp.
    Fei Shen
    Fei Shen, Managing Director - Boehringer Ingelheim Venture Fund USA Inc.
    Evan Unger
    Evan Unger, Executive Chairman and Co-Founder - NuvOx Pharma
    Stephanie Davis
    Stephanie Davis, Small Business Program Coordinator - NHLBI Innovation and Commercialization Office
  52. US Legal and Regulatory Framework, Challenges, and Opportunities for AI Use in Pharma Product Development
    This session will delve into the intricate landscape of the US legal and regulatory framework governing the use of artificial intelligence (AI) in pharmaceutical product development. As AI continues t ...
    Breakout Session
    • Regulatory Innovation
    204AB
    Moderator
    Xin Tao
    Xin Tao, Partner, Chair of U.S. Food and Drug Law Practice - Baker McKenzie
    Speakers
    Victor Liang
    Victor Liang, Senior Director, Business Analytics and Strategic Advisory - Pi Health
    Ben Rossen
    Ben Rossen, Associate General Counsel, AI Policy & Regulation - OpenAI
    Wenting Wang
    Wenting Wang, Global Head of Biomarker Statistics - Sanofi
    Rahul Gupta
    Rahul Gupta, President - GATC Health
  53. Optimizing Clinical Trial Design and Execution for Rare Diseases
    Rare disease clinical trials face unique challenges, including small patient populations, high variability in disease presentation, and logistical complexities. This panel will explore innovative stra ...
    Breakout Session
    • Orphan and Rare Disease
    254B
    Moderator
    Marshall Summar
    Marshall Summar, CEO - Uncommon Cures
    Speakers
    Emil Kakkis
    Emil Kakkis, President and CEO - Ultragenyx
    Amy Comstock Rick
    Amy Comstock Rick, Director of Strategic Coalitions, Rare Disease Innovation Hub - U.S. Food and Drug Administration
    Janet Woodcock
    Janet Woodcock, Former Principal Acting Commissioner - FDA
    Joni Rutter
    Joni Rutter, Director, National Center for Advancing Translational Sciences - National Institutes of Health
  54. The “RNAissance” Era – Recent Breakthroughs, Future Prospects, and Challenges of RNA Therapeutics
    With the development of RNA therapeutics advancing at an unprecedented pace, the healthcare and pharmaceutical industry is entering an “RNAissance” era. RNA, a molecule that was viewed as a transient ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Jean Ge
    Jean Ge, Attorney, Biotechnology Practice - Wolf Greenfield
    Speakers
    Sacha Mann
    Sacha Mann, Experienced VC / Board Member / CEO / Company Builder - Stealth biotech
    Samir Ounzain
    Samir Ounzain, Chief Executive Officer & Scientific Co-Founder - HAYA Therapeutics
    Oxana Beskrovnaya
    Oxana Beskrovnaya, Chief Innovation Officer - Dyne Therapeutics
    Jill Goldstein
    Jill Goldstein, Principle - Vida Ventures
    Benjamin Kim
    Benjamin Kim, Partner - Playground Global
  55. We Still Need the People: AI/ML Drug Discovery is Here to Stay, but we Could be its Rate Limiting Factor
    Computational methods including AI/machine learning have the potential to be transformational in biopharma by accelerating and enhancing many aspects of drug discovery to bring better drug candidates ...
    Breakout Session
    • AI and Digital Health
    257AB
    Moderator
    Alex Philippidis
    Alex Philippidis, Senior Business Editor - Genetic Engineering & Biotechnology
    Speakers
    Jennifer Chambers
    Jennifer Chambers, Senior Director of Education - Schrödinger
    Wade Davis
    Wade Davis, Senior Vice President, Head of Digital for Business - Moderna
    Anna Marie Wagner
    Anna Marie Wagner, Founder/CEO - Stealth
    Gurinder Singh “Mickey” Atwal
    Gurinder Singh “Mickey” Atwal, Chief Data and AI Officer, Pioneering Intelligence - Flagship Pioneering
    Rebecca Swett
    Rebecca Swett, Director, Computational Chemistry - X-Chem
  56. CI for the Biotech Journey: Applying Lessons from Pharma
    Whether setting a course or changing strategies in today's biopharma landscape, information overload, quickly obsolete insight, and stakeholder misalignment are industry-wide challenges. As an emergin ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Matthew Maryniak
    Matthew Maryniak, President - FENIX Group International LLC
    Speakers
    Benjamin Doran
    Benjamin Doran, Independent Consultant
    Justin Holko
    Justin Holko, Senior Vice President, Global Oncology & Hematology Business Unit - Regeneron
    Beth Vasievich
    Beth Vasievich, Head of Commercial Planning and Operations - CARGO Therapeutics
    Sarah Kleinpeter
    Sarah Kleinpeter, SVP, Head of Global Alzheimer’s and Dementia Franchise - Biogen
    Iffat Ali
    Iffat Ali, Director Competitive Intelligence, Oncology - Pfizer
  57. How Massachusetts Built a Comprehensive Education and Workforce Development Continuum
    Since 2008, Massachusetts has made significant financial, policy, and people investments in the life sciences, including building a broad-based effort to expand pathways to produce diverse talent to d ...
    Breakout Session
    • Diversity and Opportunity
    208
    Moderator
    Lauren Jones
    Lauren Jones, Secretary of Labor and Workforce Development - Commonwealth of Massachusetts
    Speakers
    Monique Cooper
    Monique Cooper, Assistant Vice Provost for Academic and Career Engagement and Success - University of Massachusetts, Boston
    Debbie Durso-Bumpus
    Debbie Durso-Bumpus, Chief People Officer - Blueprint Medicines
    Emerson Foster
    Emerson Foster, Head of Human Resources, U.S. Business Unit - Takeda
    Sunny Schwartz
    Sunny Schwartz, Chief Executive Officer - Massachusetts Biotechnology Education Foundation
  58. Closing the Practice Gaps in Precision Oncology – What are the Practical Solutions?
    While huge advances have been made in ensuring optimal patient care in oncology where diagnostic testing is required prior to initiation of therapy (i.e. precision medicine), we continue to see practi ...
    Breakout Session
    • Diagnostics and Personalized Medicine
    251
    Moderator
    Alasdair Milton
    Alasdair Milton, Principal, Precision Medicine Leader, Healthcare and Life Sciences Strategy - KPMG LLP
    Speakers
    Terri Conneran
    Terri Conneran, Cancer Survivor & Founder - KRAS Cancer Connect | KRAS Kickers
    Daryl Pritchard
    Daryl Pritchard, Senior Vice President, Science Policy - Personalized Medicine Coalition
    Lecia Sequist
    Lecia Sequist, Medical Oncologist and Program Director, Cancer Early Detection and Diagnostics Clinic - Massachusetts General Hospital
    Maria Karasarides
    Maria Karasarides, Board Member - From Testing to Targeted Treatment (FT3)
    Ralph Riley
    Ralph Riley, Global Director Precision Medicine Access and Policy Strategy - Johnson & Johnson
  59. Advancing Women’s Health Through Partnership
    The Foundation for the NIH (FNIH) creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people’s lives. Building on a ...
    Breakout Session
    • Business Development and Investment
    254A
    Speakers
    Stacey Adam
    Stacey Adam, Vice President of Science Partnerships - FNIH
  60. How to Best Coordinate U.S. Biotechnology Regulatory Policy at a National Level?
    America risks falling behind in biotechnology because it hasn't treated the sector as a strategic priority—unlike semiconductors or AI. For example, the currently fragmented and opaque regulatory syst ...
    Special Program
    • Regulatory Innovation
    209
    Moderator
    Kelly Seagraves
    Kelly Seagraves, Vice President, National Security & International Affairs - Biotechnology Innovation Organization (BIO)
    Speakers
    Jeremiah Kelly
    Jeremiah Kelly, Partner - Venable LLP
    Sarah Glaven
    Sarah Glaven, Founder, Principal - Marathon Bio
    Anastasia Bodnar
    Anastasia Bodnar, Senior Policy Advisor - National Security Commission on Emerging Biotechnology (NSCEB)
  61. Asia’s Advantage: What’s Next for Scientific Innovation Across Asia Pacific
    The Asia Pacific region is rapidly becoming a global force in healthcare and biotech innovation—fueled by resilient capital flows and propelled by its rising scientific capabilities, diverse patient p ...
    Breakout Session
    • Emerging Opportunities in Global Markets
    258A

    Sponsored by:

    johnson&johnson

    Moderator
    Alessandro Falcone
    Alessandro Falcone, Head, JLABS Singapore - Johnson & Johnson
    Speakers
    Loong Wang
    Loong Wang, CEO - QDX Technologies
    Piers Ingram
    Piers Ingram, Chief Executive Officer and Co-Founder - Hummingbird Bioscience
    Jolene Ooi
    Jolene Ooi, Partner, Healthcare - EDBI
  62. Super Session
    International Reference Pricing and Most Favored Nation Policies – Outlook and Impacts on Innovation
    On May 12, 2025, the Trump Administration announced a new Executive Order, “Delivering Most Favored Nation Prescription Drug Pricing to American Patients.” This was followed by an announcement on May ...
    Super Session
    • Special Program
    253ABC
    Moderator
    Crystal Kuntz
    Crystal Kuntz, Senior Vice President, Health Policy & Research - Biotechnology Innovation Organization (BIO)
    Speakers
    Jayson Slotnik
    Jayson Slotnik, Principal - Health Policy Strategies
    Raghav Aggarwal
    Raghav Aggarwal, Vice President - BGR Group
    Jim Meyers
    Jim Meyers, Senior Advisor
  63. Strategies for Emerging Companies in Uncertain Times: Leading CEOs Spill the Tea
    Emerging companies are the lifeblood of biotech innovation. Over time, the share of FDA-approved therapies originating from small and mid-sized biotech companies has grown steadily, now accounting for ...
    Special Program
    • Special Program
    210B
    Moderator
    Grace Colón
    Grace Colón, Chair, Bloom Science; - Board Member, BIO, Emm, MIT, Voyager Therapeutics
    Speakers
    Deborah Dunsire
    Deborah Dunsire, Chair - Neurvati Neurosciences
    Sheila Gujrathi
    Sheila Gujrathi, Chair; Director - Ventyx Biosciences and Lila Biologics; Janux Therapeutics 
    Reenie McCarthy
    Reenie McCarthy, CEO, President, and Board Member - Stealth BioTherapeutics
  64. Wednesday Featured Program: Michael Strahan
    Emmy winner, Super Bowl Champion and Peabody award winning journalist Michael Strahan currently co-anchors ABC’s “Good Morning America,” serves as an analyst for “Fox NFL Sunday,” and hosts ABC’s prim ...
    Featured Program
    • Special Program
    Main Stage
    Speakers
    Michael Strahan
    Michael Strahan - Pro Football Hall of Famer, Broadcaster, and Entrepreneur
12:30 PM (ET)
  1. Biotech M&A 2025: What’s Driving Deal-Making in The New Environment
    Currently, the biotech M&A market is subject to a confluence of unique historic forces, both promoting and opposing M&A. Some of these forces include unprecedent M&A demand from big pharma due to the ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Matthew Gardella
    Matthew Gardella, Member - Mintz
    Speakers
    William Fiske
    William Fiske, Head of M&A and Contested Situations – U.S. - Georgeson LLC
    Dan Moore
    Dan Moore, Founding Partner - Collected Strategies
    Janet Raimondo
    Janet Raimondo, Global Head Legal Transactions - Novartis
    Frank Fekete
    Frank Fekete, Managing Director - Centerview
  2. Accelerated Approval and Patient Need: The Value of Earlier Access
    The Accelerated Approval Program has been the focus of many recent conversations questioning the impact and value of the pathway for patients. Drugs approved via this pathway have become the latest vi ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    209
    Moderator
    John O'Brien
    John O'Brien, President and CEO - National Pharmaceutical Council
    Speakers
    Jeff Allen
    Jeff Allen, President and CEO - Friends of Cancer Research
    Paul Howard
    Paul Howard, Executive Director, Policy and Patient Experience Innovation - Amicus Therapeutics
    Annie Kennedy
    Annie Kennedy, Chief of Policy, Advocacy and Patient Engagement - EveryLife Foundation for Rare Diseases
    Sue Peschin
    Sue Peschin, President and CEO - Alliance for Aging Research
    Silas Martin
    Silas Martin, Head, Access and Policy Research - Johnson & Johnson
  3. An Eye on I&I: Innovations Fueling Growth
    The global immunology market is projected to nearly double by 2032, expanding from $250 billion in 2023. Immunology and Inflammation (I&I) has now emerged as a top investment priority in biopharma, su ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Allison deAngelis
    Allison deAngelis, Biotech Startups and Venture Capital ReporterBiotech Startups and Venture Capital ReporterBiotech Startups and Venture Capital Reporter - STAT News
    Speakers
    Kari Brown
    Kari Brown, Chief Medical Officer - Revolo Biotherapeutics
    Judy Chou
    Judy Chou, President and CEO - AltruBio
    Frank Nestle
    Frank Nestle, Partner and CEO of 3DC - Deerfield Management
    Jose Terencio
    Jose Terencio, Senior Vice President, Discovery - Grifols
    Daniel Baker
    Daniel Baker, Chief Development Officer - Cue Biopharma
  4. Expediting Impact: Leveraging the Patient Voice for Enhanced Clinical Trial Design and Accelerated Regulatory Approvals
    In recent years, "patient-centric" has emerged as a buzzword in the healthcare world. However, the reality is that our industry has often overlooked the patient voice, which has, at times, impeded the ...
    Breakout Session
    • Regulatory Innovation
    258A
    Moderator
    Noah Siedman
    Noah Siedman, Community & Database Manager - BDSRA Foundation
    Speakers
    Richard Wilson
    Richard Wilson, Senior Vice President, Primary Focus Lead, Genetic Regulation - Astellas
    Vicki Moulton
    Vicki Moulton, Medical Director, Clinical Development - Zura Bio
    Mathew Pletcher
    Mathew Pletcher, Chief Scientific Officer - Weaver Biosciences
    Erin Ward
    Erin Ward, Co-founder and President - MTM-CNM Family Connection
  5. Replacing Guesswork with Data: How Preclinical Human Models Are Driving More Predictive Drug Discovery
    This session will delve into how preclinical human data, derived from innovative methodologies such as organ-on-a-chip technology, lab-grown tissues, and advanced imaging techniques, can provide inval ...
    Breakout Session
    • AI and Digital Health
    210B
    Moderator
    Jarod Rutledge
    Jarod Rutledge, Director of Biotechnology and Life Sciences - Starbloom Capital
    Speakers
    Andrei Georgescu
    Andrei Georgescu, CEO & Founder - Vivodyne
    Wyatt McDonnell
    Wyatt McDonnell, CEO & Co-founder - Infinimmune
    Ashley Zehnder
    Ashley Zehnder, Co-Founder and CEO - Fauna Bio
    Carlos Bustamante
    Carlos Bustamante, CEO & Co-Founder - Galatea Bio
  6. The Landscape for Cell Therapy and Gene Therapy: Challenges and Opportunities from Drug Development to Patient Access
    An increasing number of cell and gene therapies hold significant promise, but challenges remain in bringing these therapies to patients. These include regulatory, manufacturing and clinical trial chal ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    257AB
    Moderator
    Phyllis Arthur
    Phyllis Arthur, Executive Vice President & Head of Healthcare Policy and Programs - Biotechnology Innovation Organization (BIO)
    Speakers
    Jayson Slotnik
    Jayson Slotnik, Principal - Health Policy Strategies
    Christina Hartman
    Christina Hartman, Senior Director, Government Affairs - Orchard Therapeutics
    Laura Okpala
    Laura Okpala, Executive Director, Reimbursement Policy - Gilead Sciences
  7. Company Presentations
    Company Presentation Session
    • Business Development and Investment

    Thank you to our Company Presentation sponsors:

    johnson&johnsonPharmalogic

  8. The Disorder Channel Film
    Spilled Milk - Two lifelong friends. Omar is living with Sickle Cell Disease; Jaqai has uprooted his life to make a documentary about him. Spilled Milk explores the harsh realities of Sickle Cell, bey ...
    Storytelling Stage Storytelling Stage (Booth #349)
  9. Storytelling Stage
    The Storytelling Stage is accessible to all registered attendees. You can find it located in the Exhibition Hall - Booth #349. The BIO Storytelling Stage is a showcase of the heart of BIO's priorities ...
    Storytelling Stage Storytelling Stage (Booth #349)
  10. Start-Up Stadium Thursday
    Start-Up Stadium Session
    • Business Development and Investment
    North Lobby
  11. The Innovation Race vs. Regulatory Pace: What to Do When Innovation Outpaces Regulation
    When innovating toward solutions for the world's greatest health challenges, such as matters of health security, global preparedness, and life-saving health solutions more broadly, time is of the esse ...
    Breakout Session
    • Regulatory Innovation
    204AB
    Moderator
    Angela Specht
    Angela Specht, Global Head, BARDA Alliance - Johnson & Johnson
    Speakers
    Jeremiah Kelly
    Jeremiah Kelly, Partner - Venable LLP
    Paul Kim
    Paul Kim, Principal - Kendall Square Policy Strategies, LLC
    Adora Ndu
    Adora Ndu, Chief Regulatory Officer, and Executive Vice President of Portfolio Strategy and Management - BridgeBio Pharma, Inc.
    Cory Sago
    Cory Sago, CEO - Amplitude Therapeutics
  12. Weighing in on Weight Loss Medicine
    How can obesity treatments move beyond GLP-1 drugs to offer long-term, patient-friendly solutions? Obesity management is at a pivotal phase, with new opportunities emerging to deliver sustainable weig ...
    Breakout Session
    • Next Generation Biotherapeutics
    206AB
    Moderator
    Jonah Comstock
    Jonah Comstock, Editor in Chief - pharmaphorum
    Speakers
    Steffen-Sebastian Bolz
    Steffen-Sebastian Bolz, Co-Founder & Chief Scientific Officer - Aphaia Pharma
    Punit Dhillon
    Punit Dhillon, Chief Executive Officer - Skye Bioscience
    Beverly Tchang
    Beverly Tchang, Assistant Professor of Clinical Medicine - Weill Cornell
    Michael Donnelly-Boylen
    Michael Donnelly-Boylen, Patient Advocate; Associate Dean of Enrollment and Strategic Initiatives - Roger Williams University School of Law
  13. Carving Out Your Ground in Immunology & Inflammation (I&I)
    Immunology is entering a new era, presenting unique investment prospects as therapeutic innovations emerge and investors are eager to participate in this attractive field. Next generation I&I therapie ...
    Breakout Session
    • Business Development and Investment
    210A
    Moderator
    Mark Dowling
    Mark Dowling, Head of Search & Evaluation - Immunology - Sanofi
    Speakers
    Kathy Dong
    Kathy Dong, President and Chief Executive Officer - Electra Therapeutics
    Bruce Jacobs
    Bruce Jacobs, Chief Financial Officer - Kymera Therapeutics
    Dan Koerwer
    Dan Koerwer, Chief Operating Officer - Ventus Therapeutics
    John Sundy
    John Sundy, Chief Medical Officer - Seismic Therapeutic
    Meghan Zubradt
    Meghan Zubradt, Senior Director, Business Development - GSK
  14. Can AI in Drug Discovery Deliver More Than Just Faster, Cheaper Solutions?
    As the pharmaceutical industry increasingly embraces AI in drug discovery, a pressing question emerges: can AI go beyond merely delivering faster and cheaper drugs? Join our expert panel of C-level ex ...
    Breakout Session
    • AI and Digital Health
    210B
    Moderator
    Andrew Dunn
    Andrew Dunn, Senior Biopharma Correspondent - Endpoints News
    Speakers
    Anne Carpenter
    Anne Carpenter, Institute Scientist - Broad Institute (SAB: SyzOnc, Recursion, Quiver)
    Michelle Chen
    Michelle Chen, Chief Business Officer - Insilico Medicine
    Matt Truppo
    Matt Truppo, Global Head of Research Platforms and Computational R&D - Sanofi
    Thras Karydis
    Thras Karydis, Co-Founder and Chief Technology Officer - DeepCure
  15. Physician and Patient Perspectives on the Impact of the Inflation Reduction Act on Drug Development, Access, and Innovation
    The Inflation Reduction Act (IRA) has caused strong disruption to innovation in drug development, and this impact is falling heaviest on oncology and neuroscience. Cancer drug development has been rem ...
    Breakout Session
    • Value‚ Patient Access and Reimbursement
    209
    Moderator
    Steven Potts
    Steven Potts, Chair, Drug Development Council - International Cancer Advocacy Network
    Speakers
    Barbara McAneny
    Barbara McAneny, Former President AMA ; CEO- NM Oncology Hematology Consultants Ltd, ONCare Alliance Co-Chair - New Mexico Oncology Hematology Consultants, Ltd.
    Gunnar Esiason
    Gunnar Esiason, Head of Patient Engagement and Patient-Centered Innovation - RA Ventures
    Rafael Fonseca
    Rafael Fonseca, Interim Director Comprehensive Cancer Center - Mayo Clinic, Arizonia
    Bob Hanlon
    Bob Hanlon, Co-founder and chairman - Exon 20 Group
    Duane Schulthess
    Duane Schulthess, CEO - Vital Transformation
  16. A New Era in Organ Transplantation: Advancing Xenotransplantation with Genetic Engineering
    The recent landmark success of gene-edited porcine kidney transplants into human recipients marks a turning point in the future of organ transplantation. With genetic engineering enabling immune-compa ...
    Breakout Session
    • Business Development and Investment
    252AB
    Moderator
    Angelika Fretzen
    Angelika Fretzen, Chief Operating Officer and Technology Translation Director - Wyss Institute
    Speakers
    Mike Curtis
    Mike Curtis, CEO - eGenesis
    Alex Morgan
    Alex Morgan, Partner - Khosla Ventures
    David-Alexandre Gros
    David-Alexandre Gros, CEO - Eledon
    Leonardo Riella
    Leonardo Riella, Harold and Ellen Danser Endowed Chair in Transplantation and Associate Professor of Medicine - Massachusetts General Hospital, Harvard Medical School
    Xiaoxi (Sofie) Wei
    Xiaoxi (Sofie) Wei, CEO & Co-Founder - X-Therma
  17. Enabling Gene and Cell Therapy translation from bench to clinic at Mass General Brigham’s Gene and Cell Therapy Institute (MGB-GCTI)
    With more than 30 approved gene and cell therapy (GCT) products and the rapid emergence of new GCT technologies, academic medical centers (AMCs) play a crucial role in advancing genetic medicines. How ...
    Breakout Session
    • Cell and Gene Therapy and Genome Editing
    257AB
    Speakers
    Robert Manguso
    Robert Manguso, Assistant Professor of Medicine, Harvard Medical School and Krantz Family Center for Cancer Research, Massachusetts General Hospital
    R Alexander Wesselhoeft
    R Alexander Wesselhoeft, Director of RNA Therapeutics, Gene and Cell Therapy Institute (GCTI), Mass General Brigham
    Nathan Yozwiak
    Nathan Yozwiak, Head of Research at the Gene and Cell Therapy Institute (GCTI) - Mass General Brigham
  18. Super Session
    Strengthening the Future of Biotech Investing
    Whether it is FDA, tariffs, interest rates or geopolitical uncertainty, the macro has been exerting significant pressure on the biotech industry. Will there be widespread consolidation in the number o ...
    Super Session
    • Special Program
    205ABC
    Moderator
    Steve Seedhouse
    Steve Seedhouse, Biotech Research Analyst - Cantor Fitzgerald
    Speakers
    Andrew Lam
    Andrew Lam, Managing Director, Head of Biotech Private Equity - Ally Bridge Group
    Nandita Shangari
    Nandita Shangari, Managing Director - RA Capital
    Michael Margolis
    Michael Margolis, Senior Managing Director, Head of Healthcare Investment Banking - Oppenheimer & Co. Inc.
    Rami Rahal
    Rami Rahal, Partner - MPM BioImpact
    Cindy Xiong
    Cindy Xiong, Partner - Foresite Capital
  19. The Power to Shape the Future
    Successful collaborations among biopharmaceutical companies, patient advocacy organizations, and other key stakeholders help to de-risk drug development and can avoid potentially perilous roadblocks l ...
    Breakout Session
    • Patient Advocacy
    208
    Moderator
    Paul Hastings
    Paul Hastings, President & CEO - Nkarta
    Speakers
    Karin Hoelzer
    Karin Hoelzer, Senior Director, Patient Advocacy - Biotechnology Innovation Organization (BIO)
    Jennifer McNary
    Jennifer McNary, Co-founder - Canary Advisors
    Sean Ainsworth
    Sean Ainsworth, Chief Executive Officer - Immusoft
    Kelly Barta
    Kelly Barta, Executive Director - Coalition of Skin Diseases
    Kimberly Beer
    Kimberly Beer, Senior Vice President, Policy and External Affairs - National Health Council
  20. Fueling the Future of Drug Discovery: Getting Real about AI and Data
    AI holds immense promise for helping us bring medicines to patients faster, but only if we confront the growing data dilemma. Specifically, as we aim for AI to impact each step of the drug discovery a ...
    Breakout Session
    • AI and Digital Health
    258A

    Sponsored by:
    millipore sigma

    Moderator
    Lori Ellis
    Lori Ellis, Head of Insights - BioSpace
    Speakers
    Thibault Geoui
    Thibault Geoui, Director - Zühlke
    Jeremy Jenkins
    Jeremy Jenkins, US Head of Discovery Sciences - Novartis Biomedical Research
    Kristen Tran
    Kristen Tran, Head of Automation Strategy - Gingko Bioworks
    Karen Madden
    Karen Madden, Chief Technology Officer - MilliporeSigma
    Douglas Selinger
    Douglas Selinger, Chief Executive Officer & Founder - Plex Research, Inc.
  21. Going It Alone...or Together? A Worldview Panel
    Are the nationalist trends toward investment, trade and national security policies going to divide the world into different spheres of R&D and access to health care products? What impact will they hav ...
    Special Program
    • Special Program
    Main Stage
    Moderator
    Joseph Damond
    Joseph Damond, Chair, International Trade Policy & Global Life Sciences - Crowell Global Advisors
    Speakers
    Erika Smith
    Erika Smith, CEO - EpiTET Therapeutics
    Steffen Thirstrup
    Steffen Thirstrup, Chief Medical Officer - European Medicines Agency (EMA)
    Michael Nally
    Michael Nally, CEO-Partner at Flagship Pioneering and Chief Executive Officer - Generate:Biomedicines
    Bibhash Mukhopadhyay
    Bibhash Mukhopadhyay, Venture Capital Investor
    Jennifer Sheng
    Jennifer Sheng, Head of Healthcare Equity Capital Markets - Citi
    Anthony Japour
    Anthony Japour, CEO and President - iTolerance, Inc.

BIO Membership
white squarewhite

BIO DOUBLE HELIX SPONSORS

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS

Loading

Search